A quantitative multiparametric cytochemical analysis of small cell carcinoma of the lung. by Fenwick, J
Liverpool John Moores University 
School of Biomolecular Sciences 
A QUANTITATIVE MULTIPARAMETRIC 
CYTOCHEMICAL ANALYSIS OF SMALL 
CELL CARCINOMA OF THE LUNG 
,.. 
SUBMITTED - AUGUST 1997 
Submitted as partial fulfilment of the requirements for the qualification of Ph. D. at Liverpool 
John Moores University . 
Director of Studies - Prof. D. R. Gadsdon 
School of Biomolecular Sciences 
Liverpool John Moores University 
Clinical Advisor - Dr. C. Clelland 
Histopathology Department 
Nottingham City Hospital 
ABSTRACT 
In general lung cancer has become the leading cause of cancer mortality in the Western 
World. However, geographical variations in lung cancer incidence can be seen worldwide as 
well as at a regional level within the UK, with Merseyside having the highest incidence and 
mortality. 
. 
Many previous studies have subjectively assessed two-dimensional histological 
sections of SCLC with different immunocytochemical markers. Therefore, this study was' 
initially designed to extract single whole tumour cells from routinely processed small cell 
lung cancer (SCLC) samples and to use immunocytochemical techniques on the cell 
monolayer produced. However, immunostaining was found to be not possible on these single 
cells. Therefore, serial histological sections were studied from 172 SCLC cases using 
immunocytochemical markers to cell proliferation antigens, oncoproteins and tumour 
suppressor proteins, as well as several cytochemical techniques. The immunostaining results 
were then assessed subjectively and fifty one cases were then selected on the basis of sample 
size and morphological preservation to be assessed objectively using a computerised digital, 
image analysis system. However clinical data was only available on thirty one of these cases. 
After detailed statistical analysis of the results a panel of five markers (P53, Mib1, PCNA,, 
NM23, CMYC) was shown to be of possible significance in predicting patient survival. Also 
several markers (NM23, BCL2, P53, Mibl) showed a difference in expression between the ' 
different histological sub-types of SCLC. For markers such as NM23 this is the first study in 
SCLC, whereas for markers such as BCL2 it is the first quantitative study in SCLC. 
The results generated and the conclusions reached by this study provide many directions. for 
further work to take, in terms of studying different marker combinations, further quantitation 
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1. AIMS AND OBJECTIVES 
Human small cell lung cancer (SCLC) is an extremely aggressive disease which accounts 
for approximately 25% of all lung cancer cases and is often extensively metastasized at 
the time of diagnosis. Due to the aggressive nature of the tumour any information that 
may contribute towards a greater understanding of the tumour biology of this form of 
neoplasia would be useful, as a better understanding of the biological nature of a tumour 
may lead to improvements in treatment and management. 
Initially, this study looked at developing a reliable and reproducible method for obtaining 
single whole cells from formalin-fixed, paraffin-embedded SCLC tissue. Once this 
method had been developed it was further intended to immunostain the whole cells 
obtained for various different oncoproteins and cellular proliferation markers. The results 
obtained were also to be compared to haematoxylin and eosin stained histological 
sections for comparison, so that the extra-cellular matrix could be seen and the cell 
monolayer results put into context in relation to the actual tumour specimen used. 
Eventually a reproducible technique was developed to extract single whole cells from 
routinely processed tissue, as well as a method of removing background debris for 
accurate quantitation. However, it was not found possible to reliably immunostain the 
cells thus obtained and this remained the case regardless of the permutation of 
modifications applied to the original technique. 
The study then reverted to a more conventional histological format, whereby a large 
series of SCLC serial histological sections were immunostained for a range of 
immunocytochemical markers. Following subjective analysis a proportion of these cases 
were then selected, on the basis of morphological preservation, for objective analysis 
using a digital image analysis system. This data was then subjected to statistical analysis. 
As the results were analysed it became apparent that a panel of immunocytochemical 
markers was emerging that could possibly provide useful information regarding survival 
prediction. 
To summarize, this study was originally aiming to develop a novel technique for isolating 
single whole tumour cells from routinely processed human SCLC tissue (with minimal 
background contamination) and to immunostain the cells obtained. However, after 
exhaustive technical modifications it was found to be not possible to reliably 
immunostain the single cell monolayers obtained. A serial section histological approach 
was then taken, using the same range of immunocytochemical markers proposed for use 
on the cell monolayers. After initial subjective analysis, followed by objective 
quantitation a panel of markers emerged that may provide useful survival information. 
This was a useful initial study combining immunocytochemical staining with digital 




The existence of cancer has been recognized for over 200 years and is now even thought to 
have been known to the early Egyptians. The actual term "cancer" refers to a collection of 
different diseases that generally at least have the common feature of uncontrolled growth. 
Cancers are generated by a multi step process known as carcinogenesis, which results from 
the accumulation of errors in vital regulatory pathways. Of all the types of human neoplasia 
lung cancer has the highest mortality rate, with 1992 USA statistics quoting less than 15% of 
patients surviving for five years after diagnosis (Boring, Squires and Tong, 1993). However, 
although lung cancer is the most fatal form of neoplasia it does not necessarily have the 
highest incidence, as breast cancer and prostate cancer are currently the most prevalent in 
women and men respectively in the Western world. However, there is considerable regional 
variation of lung cancer incidence even within the UK with areas such as East Anglia having 
a lower than average incidence and Merseyside having a much higher than usual incidence. 
In fact, the Merseyside lung cancer incidence figures are 30% above the average for men and 
40% above the average for women (personal communication from Mr. R. Donnelly, Head of 
the Roy Castle Cause For Hope Foundation, Liverpool). 
Generally lung cancers are categorized into two main groups, reflecting their biology and 
management; namely non-small cell lung cancers (NSCLC) and small cell lung cancers 
(SCLC), with further sub-classification according to 1981 World Health Organization (WHO) 
guidelines. Although due to the heterogeneous nature of lung cancers any classification 
system must be less than absolute. NSCLC account for approximately 75% of all lung cancer 
cases and the major subtypes are squamous cell carcinomas and adenocarcinomas. These 
tumours have a five year survival rate of roughly 10 to 20%. SCLC account for 
approximately 25% of lung cancer cases and have a five year survival rate of just 2 to 5%, 
with the average patient surviving for approximately one year after diagnosis (Richardson and 
Johnson, 1993). The high mortality rate is mainly due to the disease being at a late stage at 
the time of diagnosis, and as a result the treatment required is usually radical and rarely 
effective. If the preferred chemotherapy/radiotherapy combination is effective, the tumour is 
still likely to recur and it will then resist any further therapy. 
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One of the most important clinical features of SCLC is it's tendency for early and widespread 
dissemination via metastasis, resulting in the formation of secondary neoplasms at distant 
sites within the body such as the brain. Due to the highly aggressive nature of SCLC and the 
comparatively few studies carried out exclusively on this type of tumour (usually due to lack 
of material) only SCLC were chosen for inclusion within this study. In order to metastasize, 
tumour cells must have the ability to degrade extracellular matrix structures including the 
basement membrane (which is characteristic of SCLC). They must also be able to evade host 
immunosurveillance and to eventually form an autonomous lesion at a secondary site (Egan, 
Wright and Greenberg, 1991). Several proteases have been implicated in the degradation of 
the extracellular matrix, including plasminogen activators, cathepsins and certain 
metalloproteinases (MacDonald and Steeg, 1993). However, if a primary or metastatic 
tumour is to exceed a few millimetres in size it must develop it's own vascular network via 
angiogenesis (formation of new blood vessels), so this process is critical to metastatic 
progression. Although aggressive primary tumours such as SCLC shed many cells, less than 
0.01% of these will ultimately initiate successful metastatic colonies (Liotta and Stetler- 
Stevenson, 1990). 
Histologically, SCLC are characteristically composed of uniform, small, round cells 
classically expressing neuroendocrine tumour antigens, and often having electron dense 
neurosecretory granules (Russell, O'Mara and Raghaven, 1990). Due to their neuroendocrine 
properties SCLC are often referred to as tumours of the diffuse neuroendocrine system 
(DNES), and often produce ectopic peptide hormones including adrenocorticotrophic 
hormone (ACTH), antidiuretic hormone (ADH) and calcitonin. However, since the 
identification of the DNES the term "ectopic" is no longer appropriate, though still commonly 
used, as cells of the DNES normally produce peptide hormones. 
SCLC are often also staged by pathologists according to the extent of the tumour as either 
limited stage or extensive (Quoix, Charloux, Pepin and Pauli, 1993; Fraire, Johnson, Yesner, 
Zhang, Spjut and Greenberg, 1992; Souhami and Law, 1990; Rawson and Peto, 1990). Also, 
tumours may be sub-classified on the basis of histological subtype as either oat cell (more 
aggressive) or intermediate cell type (less aggressive), although this classification is 
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somewhat controversial with studies both supporting it (Korkolopoulou, Oates, Crocker and 
Edwards, 1993; Deb, Jackson, Subler and Martin, 1992; World Health Organization, 1982) 
and opposing it (Fraire et al, 1992; Bepler, Neumann, Holle, Havemann and Kalbfleisch, 
1989; Hirsch, Matthews, Aisner, Campobasso, Elema, Gazdar, Mackay, Nasiell, Shimosato, 
Steele, Yesner and Zettergren, 1988). However; as far as this particular study was concerned 
staging information was absent but data on histological subtype was available, so this was 
used for further sub-classification. 
The vast majority of human SCLC specimens are available only as archival material. So, in 
order to evaluate the potential value of immunocytochemical markers in SCLC it was 
essential that a large number of cases be initially studied, and therefore the main material 
used for this research was formalin-fixed and paraffin wax-embedded (i. e. routinely 
processed). Thus, this survey is a retrospective study of biopsy material generously supplied 
by Dr. Colin Clelland of Nottingham City Hospital: The majority of histological and 
immunocytochemical studies performed generally have their results assessed subjectively 
using a semi-quantitative scoring system. Part of the aim of this study was to carry out 
extensive quantitative work on routinely processed tissue using a digital image analysis 
system. The major limitation of using histological sections for quantitative evaluation is that 
invariably whole, complete cells cannot be studied due to the very nature of the sectioning 
process, and this has to be taken into account when interpreting results. Therefore, part of 
this work involved the development of a procedure to obtain single whole cells from 
formalin-fixed, paraffin wax-embedded biopsy material. Also, these cells were to be clearly 
morphologically recognizable tumour cells of direct relationship to those observed in the 
histological material. However, the cell monolayers obtained proved unsuitable for 
immunocytochemical staining, so a conventional histological serial sectioning approach was 
taken. 
As well as assessing the value of quantitative multiparametric analysis, it was also envisaged 
that the results would provide useful information regarding the fundamental cell biology of 
human SCLC. The majority of the work carried out was a retrospective study of routinely 
processed SCLC material obtained from patients at Nottingham City Hospital between 1988 
and 1995 (inclusive). 
Markers were selected based on results obtained from tumours of different human tissues, or 
as a follow up to preliminary work already carried out on lung cancers. The selected markers 
were investigated using immunocytochemical staining (as outlined in section 2.2) which 
allowed a broad range of markers to be assessed within a standardised system, and can also be 
used routinely. It was essential to develop reliable and consistent immunocytochemical 
procedures for the demonstration of candidate SCLC markers, and to ensure that these 
techniques were optimized for both subjective and objective assessment. The candidate 
SCLC markers selected fell into one of three general categories - (i) Cell proliferation 
markers, (ii) Oncogenic proteins, or (iii) Tumour suppressor gene proteins. These are 
discussed in more detail at a later stage. The results obtained were first assessed subjectively 
and then selected cases were quantitated objectively using a microscope-based, computer- 
assisted image analysis system. The quantitative results obtained were then subjected to 
critical statistical analysis in order to determine the most useful marker(s) in the diagnostic 
and prognostic assessment of SCLC. 
More information about the immunocytochemical procedures, candidate markers and the 
image analysis system used are given below. 
2.2 PRINCIPLES OF IMMUNOCYTOCHEMISTRY 
The definition of immunocytochemistry is : 
"A technique for identifying cellular or tissue constituents (antigens) by means of 
antigen-antibody interactions, the site of antibody binding being identified either by 
direct labelling of the antibody or by use of a secondary labelling method. " 
(Bancroft and Stevens, 1990). 
There are numerous immunocytochemical techniques which may be used to localize antigens, 
with varying degrees of sensitivity and specificity. These include the direct method, the two- 
step indirect method, the protein A method, the peroxidase-anti-peroxidase method, the 
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avidin-biotin method and the immunogold method. The streptavidin-biotin complex 
technique (Hsu, Raine and Fanger, 1981) was chosen for this study as it is a highly sensitive, 
reliable and commonly used technique and it does not have a black end-reaction product, so a 
positive result will not be confused with carbon deposits which are prevalent in human lung 
tissue. The principles of the procedure are outlined in detail within this section. 
Avidin is a basic glycoprotein of molecular weight 68 kiloDaltons (kD) which has an affinity 
for the small (244D), water-soluble vitamin biotin (vitamin H). Various methods have been 
devised to exploit the high efficiency and specificity of the avidin-biotin reaction. It is 
possible to conjugate up to 150 biotin molecules to one antibody molecule, so that the 
biotinylated antibody can bind to more than one avidin molecule (Robinson, Ellis and 
Maclennan, 1990) thereby enhancing the sensitivity of the reaction. However, avidin has two 
distinct disadvantages for use in immunocytochemistry. It has a high isoelectric point of 
approximately 10 and therefore is positively charged at neutral pH, so it may bind non- 
specifically to negatively charged structures such as the nucleus. The other problem is that as 
avidin is a glycoprotein it reacts with molecules such as lectins via the carbohydrate moiety, 
both of these difficulties lead to a reduced specificity of the reaction. These two problems are 
overcome with the substitution of streptavidin for avidin. Streptavidin is a protein of 
molecular weight 60kD isolated from the bacterium Streptomyces avidinii and, like avidin, 
has four high affinity binding sites for biotin. Also, streptavidin has an isoelectric point close 
to neutral pH, and as it is not a glycoprotein it does not bind lectins (Beesley, 1993). 
Various labels are available for the visualisation of the antigen-antibody reaction and these 
include fluorescent labels, colloidal metals and enzymes. Immunofluorescent techniques 
were the original labelling methods used in immunocytochemistry, with fluorescein being 
currently the most widely used fluorochrome. However, for retrospective studies the 
disadvantages definitely outweigh any advantages of this technique, a major problem being 
fixation-induced background staining, which is why this technique is usually only used on 
fresh-frozen tissue. Other problems include the non-permanence of the fluorescein label due 
to it's instability and limitations when counterstaining. Colloidal gold is the most popular 
metal label in use and is enhanced using silver in the immunogold-silver staining procedure, 
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which produces a black end-reaction product. However, any technique that produces a black 
reaction is unsuitable for work in human lung, this is due to the presence of carbon deposits 
within lung biopsies. The carbon is due to industrial pollution and is invariably present to 
some degree as a black deposit across the section, making the distinction between the carbon 
and a black positive reaction unreliable and highly subjective. 
Enzymes are the most widely used labels in immunocytochemistry because they produce a 
stable coloured reaction product suitable for light microscopy. Horseradish peroxidase (HRP) 
is the most commonly used immunocytochemical enzyme label in combination with the 
chromogen DAB (3,3'-diaminobenzidine tetrahydrochloride) which produces an insoluble, 
dark brown reaction end-product. However, this colour can still prove difficult to distinguish 
from carbon deposits in the lung. Also, the removal of endogenous peroxidase can be 
problematic and requires the use of a methanol-hydrogen peroxide mixture for removal. 
Alkaline phosphatase is the most widely used alternative to HRP and can be used with a 
variety of chromogens, usually giving a red or blue colour which provides a good contrast to 
any carbon deposits. Also, the removal of endogenous enzyme is easily achieved by adding 
levamisole to the developing solution (although this will not block the small intestine isoform 
of alkaline phosphatase). As alkaline phosphatase can be used to produce various 
chromogenic reactions the four most frequently used, non-commercial systems were 
evaluated for use within this study., The chromogens evaluated were - fast red, hexazotised 
new fuchsin, fast blue and tetrazolium, and these are discussed in detail in the methods 
section (3.1). As some of these chromogens are reported to be soluble in xylene, various 
mounting media were also evaluated, namely D. P. X., PVA, Farrant's medium and 
"Aquaperm". 
Once the histological sections have been taken to water (i. e. the wax has been removed) then 
the first step for immunocytochemistry is to flood the sections with diluted normal animal 
serum (generally rabbit for monoclonal antibodies, and non-rabbit for polyclonal antibodies) 
which effectively binds to any free immunoglobulins within the tissue and blocks protein 
binding groups, so preventing them from interfering with the immunocytochemical reaction 
and causing non-specific background staining. Then a primary antibody specific for the 
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antigen under investigation is applied to the tissue section (mouse for monoclonal antibodies, 
non-mouse for polyclonal antibodies). This is followed by the addition of a biotinylated 
secondary antibody that is specific for the primary antibody. The avidin-biotin complex that 
has been allowed to pre-form for 30 minutes at room temperature is then applied. Careful 
stoichiometric control ensures that binding sites remain free to bind with the biotinylated 
antibody, which allows the pre-formed complex to bind and results in a very high signal at the 
antigen binding site. The enzyme bound to the avidin-biotin complex is then developed so 
that the label can be visualized and quantitated. Generally, a nuclear counterstain (e. g. 
haematoxylin) is also applied so that the location of the antigen within a cell can be 
determined. It is very important that extensive washes in buffer are performed between each 
stage to ensure that the previous reactant is totally removed before the next stage is begun. 
Endogenous enzyme activity must also be blocked at some stage if an enzyme label is being 
used. For peroxidase labels the sections are treated with a hydrogen peroxide solution at the 
beginning of the procedure, whereas for alkaline phosphatase systems the levamisole block is 
added to the substrate solution used to visualize the label towards the end of the technique. 
However, the immunocytochemical detection of an antigen can be influenced by many ' 
variables, including the absolute level of antigen, affinity of the antibody for the antigen, 
duration of the incubation, sensitivity of the detection system and the consequences of 
fixation. Also, the signal given in an immunohistological assay is not linear with the 
antibody concentration (or with any other variable), and with a given set of conditions there 
will be a specific threshold below which no signal is obtained (Hall and Lane, 1994). 
The major artefact induced by fixation, as far as immunocytochemistry is concerned, is the 
masking of tissue antigens. Time, temperature, nature of the fixative used, fixative 
concentration and the availability of nearby proteins to be cross-linked are the variables 
related to the extent of masking. Proteolytic enzymes such as trypsin, pepsin and pronase are 
well known agents that can restore the accessibility of antibodies to epitopes previously 
masked by fixation (Huang, Minassian and More, 1976). However, enzymes have a limited 
range of effectiveness in paraffin sections and have been reported to possibly only break 
surface loops (Cattoretti, Pileri, Parravicini, Becker, Poggi, Bifulco, Key, D'Amato, Sabattini, 
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Feudale, Reynolds, Gerdes and Rilke, 1993). As a result heat-mediated antigen retrieval is 
now often the method of choice, either using microwaves or autoclaving ("pressure 
cooking"). 
Microwave oven heating of sections in heavy metal salt solutions has been found to increase 
the immunocytochemical detection of antigens (Shi, Key and Kalra, 1991). However, as pH 
is now thought to be the most important property of the buffer used (Shi, Imam, Young and 
Cote, 1995), then buffers such as citrate can be used instead of heavy metal salts so reducing 
the problem of toxicity. Protein denaturation is thought to be induced by the heating effect of 
the microwave oven. However, although microwave oven heating is an improvement in 
antigen retrieval compared to enzymes, the most appropriate buffer (and it's pH) and the 
optimum irradiation time have to be determined for each antibody under investigation (Evers 
and Uylings, 1994). 
Another novel technique that is reported to be possibly more effective than microwave oven 
heating is wet autoclave pretreatment ("pressure cooking"), which involves the immersion of 
dewaxed slides into superheated citrate buffer. It has been proposed that the presence of 
citrate ions at the temperature of superheated steam (120°C to 130°C) is necessary for the 
antigen unmasking (Bankfalvi, Navabi, Bier, Bocker, Jasani and Schmid, 1994). Another 
author reports that further protein denaturation together with the rupture of some of the 
aldehyde cross-links is the mechanism of action (Norton, Jordan and Yeomans, 1994). 
However, an important point to bear in mind concerning antigen retrieval is that because it 
markedly alters antigen detection thresholds, it may lead to situations where many cells 
become falsely positive (McKee, Hobbs and Hall, 1993), so affecting the results obtained. 
In order for the immunocytochemical technique to be as sensitive as possible, all the assay 
parameters need to be optimized. This means that for each monoclonal and/or polyclonal 
antibody being used the optimum antibody concentration, optimum antibody incubation time 
and incubation temperature must all be determined. Also, the most appropriate form of 
antigen retrieval should be determined along with exposure times, concentrations and buffers 
to be used. Steps should also be taken to ensure that reagents do not evaporate off the 
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sections during incubation (this is likely with the small quantities being used) and that the 
washing steps are extensive enough to remove all unbound reagent before the next step. 
A problem at any stage in the immunocytochemical procedure (especially the early stages) 
can lead to false negative or positive results or high background staining levels, making 
analysis impossible. In order to ensure that the technique is running correctly each time it is 
performed control sections should always be included. These should consist of two 
histological sections of tissue that is known to be positive for the target antigen, one of which 
is taken through the whole technique normally (positive control) and one of which has no 
primary antibody applied (negative control) but is otherwise treated as the positive control 
and the test sections. The use of these controls each time ensures that the results obtained are 
valid and reproducible, and goes some way towards providing an element of inter-assay 
quality control. 
2.3 CELL PROLIFERATION 
Cell proliferation is one of the most fundamental of biological processes (Hall and Levinson, 
1990). The control of proliferation, like other cellular responses, depends upon interlinked 
systems of intracellular communication. The multiple elements that complete the regulatory 
pathways collectively allow fine control of cell proliferation and provide a system of checks 
and balances that is a barrier to disordered growth. The concept of the cell cycle and it's 
division into several phases was introduced by Howard and Pelc in the 1950's. The diagram 
below outlines the various stages. After M (mitosis) phase the daughter cells enter G, (first 
gap) phase, the length of which varies according to the tissue type. They then enter S 
(synthetic) phase where DNA replication occurs, and this is followed by a second gap (G2) 
phase before cells divide again. G. is effectively a phase where cells can rest before re- 
entering the cell cycle. 
The time between the two mitoses is referred to as the cell cycle time and varies depending on 
the length of the G, phase. G, is also where the most regulation occurs and where growth 
factors and proliferation inhibitors act (Quinn and Wright, 1990). 
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CELL DEATH 
Figure 1: The Cell Cycle 
Many studies of tumour cell kinetics have indicated a relationship between high cell 
proliferation rates and tumour aggressiveness but this also obviously depends on the tumour 
cell death rate (see section 2.6). There are a variety of different methods available for 
measuring cell proliferation, including mitotic counts, thymidine labelling index and 
bromodeoxyuridine incorporation, flow cytometry, and immunocytochemistry using cell 
cycle specific antibodies. 
The mitotic count is a subjective technique, the validity of which remains controversial, and 
is defined as the number of mitoses per ten high powered fields. It is subject to many errors, 
not least of which is inter-observer variation, plus it takes no account of cell size and is 
generally non-reproducible (Quinn and Wright, 1990). In addition, it is not an independent 
parameter of cell proliferation but requires further pathological and clinical information for 
interpretation of the results. Another drawback is that this technique is only a measure of the 
proliferating cells that are actually in M phase. The thymidine labelling index (TLI) and 
bromodeoxyuridine (BrdU) incorporation both measure the percentage of tumour cells in S 
phase of the cell cycle, but they do not measure the duration of that S phase. Therefore, it is 
possible for a tumour to have a slow proliferation rate but high TLI and BrdU indices. Other 
disadvantages of these techniques include the requirement of fresh tissue and specialized 
equipment that would not be routinely available, plus the techniques are time consuming. 
Also, for use in humans the practice of in vivo administration is not justifiable. Flow 
cytometry, although widely used, does not take into account the heterogeneity of tumour cell 
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populations or the presence of normal cells, and the spatial relationships of cells to each other 
is lost. It can deliver faster results than immunocytochemical evaluation, but does not 
provide as much morphological information (Crocker, 1994), as the tissue architecture is 
destroyed when the cell suspension that is required as a sample is prepared. Therefore 
immunocytochemistry was the method of choice for this study as on balance it was the best 
method available. 
2.3.1 Proliferating Cell Nuclear Antigen (PCNA) 
There are several cell cycle specific antigens that when detected immunohistologically are 
known to provide important information about cell proliferation state, the most well known of 
which are Proliferating Cell Nuclear Antigen (PCNA) and Ki67 or Mibl (see section 2.3.2). 
PCNA, which is also known as cyclin, is an auxiliary protein for DNA polymerase S and is an 
absolute requirement for DNA synthesis. PCNA represents a 36kD acidic, non-histone 
protein which can be demonstrated in routinely processed tissues (Garcia, Coltrera and Gown, 
1989) and so can be used in retrospective studies. It has been found to be maximally elevated 
in late G, and S phase of the cell cycle and is also expressed in DNA synthesis associated 
with DNA repair. PCNA results require careful interpretation as it has now been found to be 
expressed in some non-cycling cells (McCormick, Chong, Hobbs, Datta and Hall, 1993). 
This may be due to the long half-life of the detectable protein, which is over 20 hours, or the 
presence of malignant cells inducing PCNA expression in adjacent normal cells. Also, 
PCNA is often present at very low levels in non-cycling cells so that upregulation can occur 
upon entry into the cell cycle, so PCNA is generally only considered as being totally down- 
regulated in long term quiescent cells (Wolf and Dittrich, 1992). There are several different 
antibodies to PCNA which recognize different epitopes and there are differences in the effects 
of fixation and processing on the detectability of these epitopes. PC10 is the antibody that is 
most commonly used as this has been found to recognize the epitope most resistant to 
formalin fixation (Wolf and Dittrich, 1992). 
2.3.2 Mibl 
The Ki67 (or MibI) antigen was first identified in 1983 by Gerdes, Schwab and Stein and has 
been confirmed as a nuclear antigen expressed only on proliferating cells. The actual Ki67 
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antibody has been shown to recognize a nuclear non-histone protein doublet of molecular 
weights 395 and 345kD. The Ki67 antigen has been shown to be expressed at all stages of 
the cell cycle except Goland early G,, but the actual level has been reported as varying 
throughout the cell cycle with a maximum during G2 and M phases (Crocker, 1994). 
However, there is evidence that in nutritionally deprived cells (which are common in 
tumours) there can be a discrepancy between Ki67 immunoreactivity and other parameters of 
cell proliferation (Brown and Gatter, 1990). Prior to the latest antigen retrieval developments 
(see section 2.2) Ki67 monoclonal antibodies were only suitable for work on frozen sections, 
although they have now also been found to work on fixed tissue using microwave antigen 
retrieval (Cuevas, Jones and Wright, 1993). An antibody designated as Mibl was raised to 
recognize the Ki67 epitope on routinely processed material (Cattoretti, Becker, Key, 
Duchrow, Schluter, Galle and Gerdes, 1992) before it was found that Ki67 could be used, 
however, the results obtained with Mibl are still reported to be much stronger (Cuevas et al, 
1993). Other antibodies to different cell cycle related antigens are also available, but these 
are generally less well characterized and less reliable (Crocker, 1994). There are several 
points to bear in mind when assessing cell proliferation, such as that the results will give an 
indication of cell proliferation state but not rate and as most tumours consist of heterogeneous 
cell populations there will be different proliferation rates within a tumour. 
2.3.3 AgNORs 
Nucleolar organizer regions (NORs) are chromosomal segments in which rRNA is encoded, 
and in the human karyotype they are located on each of the short arms of the chromosomes 
13,14,15,21 and 22. The acidic non-histone proteins associated with these areas were found 
to be argyrophilic and are referred to as AgNORs, although it is important to bear in mind 
that only transcriptionally active NORs bind silver (Crocker, 1996). The AgNOR silver 
staining reaction was first described in 1975 (Goodpasture and Bloom) as a three-step 
method, and has since been modified to a one-step method (Howell and Black, 1980) and the 
reaction temperature has been lowered to 20°C from 60°C (Ploton, Menager, Jeanneson, 
Himber, Pigeon and Adnett, 1986). By means of the AgNOR procedure interphase 
NORs 
appear as well defined black dots (1-2µm diameter), distributed within the nucleolar 
body, 
which can be easily quantified either subjectively (using x100 oil immersion) or objectively 
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using image analysis (Ruschoff, Plate, Contractor, Kern, Zimmermann and Thomas, 1990 ; 
Derenzini and Trere, 1991 ; Botticelli, 1996). 
They have often been described as being more numerous in malignant cells in comparison to 
normal cells and there is still some argument about whether this reflects a rise in cell 
proliferation (Janmohamed, Murray, Crocker and Leyland, 1990 ; Smith, Skilbeck, Harrison 
and Crocker, 1993) or merely an increase in cell protein production (Underwood and Giri, 
1988), but either way AgNOR status gives an indication of malignancy. However, AgNORs 
have been quoted as increasing from early Gl phase and reaching a maximum in S phase (as 
proliferation antigens do) (Derenzini and Ploton, 1994). 
AgNOR counts have previously been found useful for differentiating between low grade and 
high grade non-Hodgkin's lymphomas (Crocker and Nar, 1987), as well as for differentiating 
between benign and melanocytic lesions of the skin (Egan and Crocker, 1988). Also, a study 
of AgNORs in NSCLC found interphase AgNOR quantitation to be of prognostic value 
(Kaneko, Ishida, Sugio, Yokoyama and Sugimachi, 1991), whereas Boldy, Ayres, Crocker, 
Waterhouse and Gilthorpe (1991) reported AgNOR counts as being of little value in 
squamous cell carcinoma of the bronchus. However, AgNOR counts have been shown to be 
of no use in distinguishing between SCLC and bronchial carcinoids (Benbow and Cromie, 
1989), although they can help in identifying lymphocyte infiltrates within SCLC (Crocker, 
Ayres and McGovern, 1987). 
The AgNOR technique has some associated problems, such as precipitates across the section, 
which have limited it's routine use and interpretation, despite various proposed chemical 
modifications and physical barrier techniques. However, it has been found possible to stain a 
section for both AgNORs and immunocytochemical markers and so study two parameters 
simultaneously (Janmohamed et al, 1990). 
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2.4 ONCOGENES 
Protooncogenes are normal cellular genes that become "activated" to oncogenes through 
particular mutations so that either the normal protein is overexpressed or a mutant protein is 
produced. Activation of oncogenes may occur by mutation, chromosomal translocation, gene 
amplification or deregulation of protein expression. There are two main classes of 
oncogenes, these being (a) dominant oncogenes - require a change in a single allele to become 
oncogenic, and (b) recessive oncogenes or tumour suppressor genes (see section 2.5) - require 
a change in both alleles. Examples of oncogenes activated in lung cancer include ras, raf, jun 
and abl, however, the ras family is rarely overexpressed in SCLC and the rest have not been 
widely studied. For these reasons the oncogene proteins studied were C-MYC, C-ERBB-2, 
MDM-2, BCL-2, NM23, P53 and RB. 
2.4.1 C-MYC 
The v-myc oncogene was initially identified in the MC29 avian retrovirus and belongs to a 
family of oncogenes with high evolutionary conservation. In humans the family is known to 
consist of five members - C-myc, N-myc, L-myc, R-myc and B-myc (LeGouy, 1987) that 
code for nuclear phosphoproteins which bind to DNA and are presumed to have 
transcriptional regulatory functions. Activation of these genes usually occurs by mechanisms 
other than mutation e. g. gene amplification, rearrangements and point mutations have all been 
reported (Gazdar, 1992). Approximately 80-90% of SCLC overexpress a myc gene, however, 
only one member of the family may be amplified in a given tumour, with c-myc being the 
usual amplification noted in SCLC cases (Kern and Filderman, 1993). Whereas amplification 
of the myc genes in NSCLC is much less common (Gazdar, 1992). The c-myc gene has been 
mapped to chromosome 8q24 and codes for a 64-67kD protein. Anderson and Spandidos 
(1993) found an apparent correlation between the degree of c-myc gene amplification in the 
primary tumour and the patient survival time. Cmyc has also been implicated to participate in 
DNA replication by influencing the initiation of DNA synthesis (Prins, DeVries and Mulder, 
1993). Expression of C-MYC appears to be associated with a cellular state 
in which DNA 
replication occurs provided suitable extrinsic factors are present, but from which cells 
die by 
the process of apoptosis (see 2.6) should these factors be withdrawn (Evan, Wyllie, Gilbert, 
Littlewood, Land, Brooks, Waters, Pann and Hancock, 1992). 
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2.4.2 MDM2 
The human mdm2 (mouse double minute 2) gene is located on chromosome 12g13-14 and is 
often found to be amplified in sarcomas. The 90 kD MDM2 protein is capable of forming a 
complex with mutant or wild-type P53 (see section 2.5.1) and suppressing its transactivation 
function (Bueso-Ramos, Yang, DeLeon, McCown, Stass and Albitar, 1993). When MDM2 
protein is expressed in a cell where P53 is active it blocks further P53 function, which results 
in less MDM2 being made, so the activity of P53 and levels of MDM2 in a cell are kept in 
balance by this autoregulatory feedback loop (Wu, Bayle, Olson and Levine, 1993). Factors 
that act to increase MDM2 levels or increase MDM2 activity will promote cell proliferation, 
whereas factors that alter the ability of P53 protein to stimulate MDM2 or inactivate MDM2 
should lead to growth arrest. MDM2 has been shown to be able to overcome the G, arrest 
capability of both P53 and RB (see section 2.5.2) as well as enhancing the activity of the 
growth promoting transcriptional activator E2F. 
2.4.3 C-ERBB-2 
The neu oncogene was first identified in a chemically induced rat neuroblastoma by 
Schechter, Hung, Vaidyanathan, Weinberg, Yang-Feng, Francke, Ullrich and Coussens in 
1984. The human equivalent of the rat neu gene was independently cloned from a cDNA 
library and was called HER-2 (Coussens, Yang-Feng, Liao, Chen, Gray, McGrath, Seeburg, 
Libermann, Schlessinger, Francke, Levinson and Ullrich, 1985), however, after cloning from 
genomic DNA it was designated as c-erbB-2 (Semba, Kamata, Toyoshima and Yamamoto, 
1985) and has been mapped to chromosome 17g21. The c-erbB-2 gene (erythroblastoma-2) 
encodes a transmembrane, tyrosine-specific protein kinase called p185n", which is a putative 
growth factor receptor, related in sequence and structure to the epidermal growth factor 
receptor (EGFR). EGFR and p185"`° plus the proteins encoded by the genes c-erbB-3 and c- 
erbB-4 form the EGFR superfamily (Pastan, 1993). Amplification or overexpression of the 
protein has been indicated as a negative prognostic factor in breast cancer. pl85"" has been 
found to be overexpressed in NSCLC, and to indicate shortened survival times in lung 
adenocarcinomas (Kern, 1990). A lack of c-erbB-2 mRNA and protein expression has been 
reported as a unique feature of SCLC, with possible diagnostic relevance (Schneider, Stohr, 
Spies, Bohm, Fink, Manning, Nekarda, Prauer and Roth, 1992). 
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2.4.4 BCL-2 
The bcl-2 protooncogene (B cell leukaemia and lymphoma gene 2) was originally discovered 
at the chromosomal breakpoint of the translocation 14; 18 found in human follicular 
lymphoma. The translocation juxtaposes the bcl-2 gene from chromosome 18 with the 
immunoglobulin heavy chain locus on chromosome 14. As a result abnormally high levels of 
BCL-2 protein are produced, although expression of the protein is not specific to this 
translocation as it is also seen in normal tissue and other malignancies. The bcl-2 gene is 
believed to be localized to the inner mitochondrial membrane (Hockenbery, Nunez, Milliman, 
Schreiber and Korsmeyer, 1990) and codes for a 26kD protein. The bcl-2 gene family 
contains several members including bcl-2, bax, bcl-x and bak, all of which show structural 
homology (Lu, Abel, Foster and Lalani, 1996). 
High levels of BCL-2 expression prevent cell death from a wide variety of cell stresses and 
cytotoxic chemicals, including growth factor depletion, heat shock, ionising radiation and a 
range of chemotherapeutic drugs (Fanidi, Harrington and Evan, 1992 ; Bissonnette, 
Echeverri, Mahboubi and Green, 1992). In oncogenesis, the deregulation of BCL-2 
expression may contribute to the accumulation of mutations by suppressing the apoptotic 
deletion of cells that normally follows DNA damage. BCL-2 has the ability to bypass P53- 
dependent and independent apoptotic pathways (Chiou, Rao and White, 1994). BCL-2 may 
act in concert with C-MYC in cell transformation, by suppressing the cell death pathway 
promoting function of c-myc. Other studies have shown that CMYC and BCL-2 can co- 
operate to overcome P53-induced growth inhibition by the exclusion of P53 from the nucleus 
during a critical period in G, phase (Ryan, Prochownik, Gottleib, Apel, Merino, Nunez and 
Clarke, 1994). Whilst BCL-2 expression may inhibit cell death it does not enhance 
proliferation, and although the rescue of cells from apoptosis by BCL-2 can occur at any stage 
of the cell cycle the actual mechanism of apoptotic inhibition is unclear (Lu et al, 1996). 
BCL-2 protein has been reported as being absent in differentiated cells of normal bronchial 
epithelium, however, abnormal expression has been found in bronchial dysplasias of all 
histological grades, suggesting that changes in the expression of this molecule arise early in 
the transformation of normal to dysplastic epithelium (Walker, Robertson, Myskow and 
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Dixon, 1995a). In NSCLC, BCL-2 overexpression has been found to be related to better 
overall survival and a less aggressive tumour phenotype (Pezzella, Turley, Kuzu, Tungekar, 
Dunnill, Pierce, Harris, Gatter and Mason, 1993 ; Fontanini, Vignati, Bigini, Mussi, Lucchi, 
Angeletti, Basolo and Bevilacqua, 1995). SCLC cell lines have been found to express high 
levels of BCL-2 protein (Ikegaki, Katsumata, Minna and Tsujimoto, 1994), and other studies 
have found the majority of SCLC tumour samples to be positive for BCL-2 expression (Jiang, 
Sato, Kuwao and Kameya, 1995 ; Yan, Chen, Tsai and Jin, 1996). However, the expression 
of BCL-2 was not found to be of any prognostic significance in this tumour type (Yan et al, 
1996). Due to it's expression in neuroendocrine tumour types (such as SCLC) and it's close 
correlation with neuroendocrine markers, BCL-2 has been suggested as a possible marker of 
neuroendocrine differentiation (Jiang, Kameya, Sato, Yanase, Yoshimura and Kodama, 
1996). 
2.5 TUMOUR SUPPRESSOR GENES 
2. S. 1 PS3 
The P53 protein was discovered in the late 1970's as a cellular 53kD nuclear phosphoprotein 
(hence the name p53) bound to the large transforming antigen of the SV40 DNA virus (Lane 
and Crawford, 1979). The actual p53 gene itself has now been mapped to chromosome 17. 
p53 mutations are generally regarded as being the commonest abnormality in human 
malignancies. The wild type (normal) P53 protein is usually found in the cell nucleus, but it 
has a very short half-life and is present in such small quantities that it cannot be detected by 
immunohistochemistry. However, mutant P53 accumulates to levels that allow detectability 
by immunohistochemical systems. Approximately 90% of P53 mutations are missense 
mutations, causing one amino acid to be substituted for another, usually altering protein 
conformation and causing nuclear accumulation (Harris, 1993). Different carcinogens have 
been found to cause different characteristic mutations, for example, the predominant base 
change found in lung cancer is aG to T transversion believed to be caused by the carcinogen 
benzo(a)pyrene present in tobacco smoke (Mazur and Gluckmann, 1988). 
Kastan, Onyekwere, Sidransky, Vogelstein and Craig (1991) have shown that accumulation 
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of P53 mediates arrest of the cell cycle at G, phase. Normal P53 monitors the integrity of the 
genome. If DNA is damaged, P53 accumulates and switches off replication to allow extra 
time for repair, and if repair fails P53 may trigger apoptosis. Tumour cells where P53 is 
inactivated by mutation cannot carry out this cell cycle arrest, therefore they are generally less 
stable and will accumulate mutations and chromosomal rearrangements at an increased rate, 
leading to rapid selection of malignant clones (Lane, 1992). The halting of the cell cycle is 
believed to be due to the protein product of the WAF1/Cipl gene which is under p53 
transcriptional control. Recent studies investigating the mechanisms underlying the 
biological activity of P53 indicate that the protein is involved in gene transcription, DNA 
synthesis and repair, genomic plasticity and apoptosis (Greenblatt, Bennett, Hollstein and 
Harris, 1994). P53 also has the ability to form complexes with other cellular proteins as well 
as viral oncoproteins which bind to P53 and alter it's ability to interact with cellular proteins. 
MDM2 (see section 2.4.2) is one of the cellular proteins that can bind to P53 and inhibit it's 
transcriptional activity. 
Various studies agree that P53 mutations occur at a higher frequency in SCLC (approx 70%) 
compared to NSCLC (approx 20 - 30%) (Miller, Simon, Aslo, Kok, Yokota, Buys, Terada 
and Koeffler, 1992 ; Fontanini, Bigini, Vignati, Macchiani, Pepe, Angeletti, Pingitore and 
Squartini, 1993). However, studies have shown no increase in P53 protein levels in 
pulmonary carcinoids (Iggo, Gatter, Bartek, Lane and Harris, 1990). There are, however, 
several controversial aspects of P53 assessment, such as the time when the P53 mutations 
appear. In 1994 Fontanini, Vignati, Bigini, Merlo, Ribecchini, Angeletti, Basolo, Pingitore 
and Bevilacqua found no P53 immunoreactivity in histologically normal epithelium, 
hyperplastic epithelium or squamous metaplastic lesions. However, Walker, Dixon and 
Myskow (1995b) found the abnormal expression of P53 protein to be an early though not 
obligatory event in lung cancer development that may precede visible histological change. 
The use of antigen retrieval in P53 immunohistochemistry is also a controversial area. 
Hall and Lane (1994) recommended that care is needed when interpreting P53 results, as a 
positive P53 reaction may be due to the accumulation of wild type protein caused by DNA 
damage. Baas, Van den Berg, Mulder, Clement, Slebos, Hamilton and Offerhaus (1996) have 
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also recommended a limit to the extent of which antigen retrieval should be used for P53 
immunohistochemistry. 
2.5.2 Retinoblastoma (RB) 
The rb gene was first identified in retinoblastoma, a rare form of paediatric eye tumour 
(Knudson, 1971) and encodes a nuclear phosphoprotein (p110'ß) that is associated with DNA 
binding activity. The rb gene has been mapped to chromosome 13g14. The RB protein is 
phosphorylated in an undulating fashion throughout the cell cycle. It becomes 
hyperphosphorylated in late G, and remains so in S, G2 and M phases. Cells in G, and Go 
express RB in an underphosphorylated form. This regulation of phosphorylation during the 
cell cycle suggests that the RB protein acts as a cell cycle regulator, the inactivation of which 
may lead to unbridled cell growth (Hensel, Hseih, Gazdar, Johnson, Sakaguchi, Naylor, Lee 
and Lee, 1990). The cell cycle-dependent phosphorylation of the RB protein is mediated by 
activated cyclin D-cyclin dependent kinase (CDK) complexes during G, (Sakaguchi, Fujii, 
Hirabayashi, Yoon, Komoto, Oue, Kusafuka, Okada and Maksuda, 1996). Several studies 
have shown that many, if not all, of the phosphorylations of RB protein are carried out by 
cyclins and CDKs (Hinds and Weinberg, 1994). Xiao, Chen, Levine, Modjtahedi, Xing, 
Sellers and Livingston (1995) showed that MDM-2 interacts with the RB protein inhibiting 
it's growth regulatory function. RB protein can protect cells from P53-induced apoptosis as 
well as non P53-induced apoptosis, although the mechanism of protection remains obscure 
(Kouzarides, 1995). 
Inactivation of RB is a frequent event in SCLC. Harbour, Lai, Whang-Peng, Gazdar, Minna 
and Kaye (1988) found RB abnormalities to be a common event in both SCLC and 
pulmonary carcinoids but rare in other lung tumour types. Another study in 1994 by 
Higashiyama, Doi, Kodama, Yokouchi and Tateishi also found complete lack of RB protein 
expression in the majority of SCLC patients (88%) and regarded it as possibly a minor event 
in NSCLC. It has been suggested that inactivation of the rb gene in SCLC may be correlated 
not only with the initiation of the tumours but also with tumour development in terms of 
aggressiveness of biological and clinical behaviour. 
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Z S. 3 NM23 
nm23 (non-metastasizing gene 23) is a candidate metastasis suppressor gene first identified in 
1988 by Steeg, Bevilacqua, Kopper, Thorgeirsson, Talmadge, Liotta and Sobel. In 1991 
Stahl, Leone, Rosengard, Porter, King and Steeg found a second nm23 gene (nm23-H2) that 
was 81% identical to the first nm23 gene (nm23-H1), both of which produce 17kD proteins. 
Both nm23 genes have been localized to chromosome 17g21 (Backer, Yendola, Kovesdi, 
Fairhurst, O'Hara, Eddy Jr, Shaws, Mathew, Murty and Chaganti, 1993). Reduced 
expression of the nm23-H 1 mRNA content has been correlated with reduced survival in 
breast cancer (Hennessey, Henry, May, Westley, Angus and Lennard, 1991). Reduced 
expression of NM23-H 1 has also been associated with distant metastases of human 
hepatocellular carcinoma (Nakayama, Ohtsuni, Nakao, Shima, Nakata, Watanabe, Ishii, 
Kimura and Nagataki, 1992) and with the early appearance of metastases after diagnosis of 
malignant melanoma (Florenes, Aamdal, Myklebost, Maelandsmo, Bruland and Fadstad, 
1992). However, in squamous cell carcinoma of the lung high levels of nm23 mRNA have 
been correlated with advanced stages of the disease, thereby not exhibiting a metastasis . 
suppressor function (Engel, Theisinger, Seib, Seitz, Huwer, Zang, Welter and Dooley, 1993). 
To date there have been no published studies investigating the expression of nm23 gene or its 
protein product in SCLC. 
2.6 APOPTOSIS 
There are two major categories of cell death - necrosis and apoptosis. Necrosis is a 
pathologic form of cell death that often occurs as a result of massive tissue damage and 
results in the deletion of large numbers of cells. Apoptosis (also called programmed cell 
death) describes a process where single cells may be deleted in the midst of living tissue. The 
two processes also exhibit distinctly different morphological characteristics. In necrosis the 
cell loses it's homeostatic control and becomes swollen with fluid, eventually leading to cell 
lysis and release of the intracellular contents, which in turn stimulates the inflammatory 
process (Arends and Harrison, 1994). In apoptosis the cell shrinks and loses contact with 
neighbouring cells, followed by a loss of specialized cell surface structures such as microvilli 
and cell-cell junctions. Apoptotic bodies (membrane-bound vesicles) are then produced, and 
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these are rapidly recognized and removed by macrophages and neighbouring cells before the 
inflammatory process can be stimulated (Wyllie, 1992). 
The actual process of apoptosis was first recognized by Kerr, Wyllie and Currie in 1972. 
Apoptosis is a normal physiological process that is important in embryogenesis, immune 
development and other normal body processes. Many cancer treatments also rely on the 
induction of apoptosis and may be one mechanism responsible for the development of drug 
resistance (Arends and Harrison, 1994). The role of oncogenes and tumour suppressor genes 
in the prevention and induction of apoptosis is now becoming widely recognized (see sections 
2.4 and 2.5). Also enzymes such as interleukin-1 p converting enzyme (ICE) and ICE-like 
cysteine proteases are capable of inducing apoptosis in susceptible cells. These oncogenes 
and enzymes provide a promising area of interest for the development of new methods for the 
detection of apoptosis. The problem with quantitating apoptosis is that the morphological 
characteristics exist for only 1-2 hours, so the window of detection is relatively small, leading 
to under-estimation of the apoptotic population. The latest detection method to be proposed 
is the in situ-end labelling (ISEL) technique, which is also referred to as the TUNEL 
technique, for use on histological sections (Gavrieli, Sherman and Ben-Sasson, 1992 ; 
Wijsman, Janker and Keijzer, 1993). Gaffney, O'Neill and Staunton (1995) found that the 
ISEL technique was able to identify cells in the early stages of apoptosis in SCLC, however, 
false positives due to exogenous/endogenous mutations are a possibility with this technique. 
Moser (1995) has also described a modified silver stain that detects the argyrophilia exhibited 
by clumped chromatin in apoptotic cells. 
2.7 QUANTITATION 
The classical evaluation of a microscopic sample in pathology is based on the visual analysis 
of the image with the aim of detecting and classifying it's diagnostic features. These 
characteristics are compared with commonly approved schemes (e. g. WHO classification of 
tumours). The interpretation of the microscope image, which provides valuable information 
for individual therapy, depends a great deal on a subjective view and subjective decision 
making capability, based on the individual's experience. The subjective element in the 
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diagnosis can result in divergence of opinions between individuals (Julis, University and 
Mikes, 1992). However, a conventional tissue section represents only a2 dimensional image 
of 3 dimensional structures, but this can be overcome using techniques such as stereology or 
confocal microscopy, however, they require specialized equipment which was unavailable for 
this study and are also unlikely to be used routinely in hospital laboratories. Computerized 
image analysis is the term used to describe that area of work that utilizes computers in the 
morphometric measurements of histological or cytological features. The ability of computers 
to display complex graphics and digitally stored images has greatly enhanced the analysis of 
visual data. Machine vision cannot replace classical visual diagnosis but enables new and 
reproducible criteria to be introduced into the subjective decision making process, and a more 
precise assessment to be made of some biological features important for the estimation of 
prognosis and diagnosis. 
Computerized image analysis systems simulate, in a limited way, the function of the human 
brain. Characteristic features of the colour signal captured by the camera are sent to the 
image processor and analysed. These features include saturation which corresponds with 
stain purity, hue which represents the principal wavelength and intensity (or luminance) 
which is the sum of the intensities of received light in each of it's 3 red, green and blue 
channels. The analysis of a reaction product in real colours used to represent a major obstacle 
for many image analysis systems. To circumvent the problem of making densitometric 
measurements in colour, only one colour channel is selected at any one time. From the red, 
green and blue components the one should be chosen which undergoes the maximum 
absorption by a coloured reaction product (Julis et al, 1992), in a similar way to conventional 
spectrophotometers. 
In conventional histological sections the whole cell is never seen, due to the very nature of the 
sectioning process, therefore a technique was developed from that proposed by Van Driel 
Kulker, Mesker, Tanke, Feichtinger and Ploem (1985) to obtain whole cells from formalin- 
fixed, paraffin-embedded tissue. The theory was to produce a monolayer of single, whole 
tumour cells on a slide which were capable of being stained both by routine histological 
methods and by immunocytochemical techniques (see section 3.18). Used in conjunction 
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with histological sections from the same material it was hoped to obtain quantitative data (as 
in flow cytometry) with the maximum morphological information (as in histological 
immunostaining). 
The only chromogenic stain that has gathered worldwide acceptance for DNA 
cytophotometry is the Feulgen reaction (1924), as it is currently the only histological staining 
technique which is stoichiometric for DNA i. e. the staining of DNA is both quantitative and 
specific (McCormick and Hall, 1994). The Feulgen reaction starts with acid hydrolysis where 
the purine bases are removed from the DNA and the apurinic acid molecule produced is 
degraded. These two reactions have their own kinetics and produce a reaction curve known 
as the hydrolysis profile which has 4 phases with the plateau (phase III) being the point of 
optimum hydrolysis. The use of hot acid produces a short profile and it may be difficult to 
stop the reaction at the plateau, whereas in cold hydrolysis (using a higher concentration of 
acid at room temperature) the plateau phase lasts several minutes. After acid hydrolysis the 
sections are placed in Schiffs reagent which binds covalently to the exposed aldehyde groups, 
producing a bright magenta colour. 
Various studies have been performed on tumour nuclei stained by the Feulgen technique and 
quantitated by image analysis systems. Kayser, Shite and Tocke (1993) showed that the 
measurement of nuclear DNA content was not associated with tumour size or lymph node 
infiltration. DNA content has been shown to have a tendency to increase through the 
sequence from typical carcinoids to atypical carcinoids to SCLC (Larsimont, Kiss, DeLaunoit 
and Melamed, 1990), and may have a role in the distinction of premalignant and non- 
premalignant squamous dysplasias (Aufferman and Bocking, 1985). In SCLC the cell 
dimensions are partly dependent upon the size of the biopsy and the difficulty of studying 
these lesions objectively was emphasized by Vollmer (1982), but Thunnisson and 
Diegenbach (1986) disagreed with these findings. In order to ensure any degree of 
reproducibility within the image analysis system controls must be used, and these can be 
provided by the use of lymphocytes within sections as these are known diploid cells and so 
provide a reference against which malignant nuclei can be measured. 
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A large portion of this work involved the development or evaluation of methods (see section 
3) for use with the image analyser. As immunohistochemistry was so important for this study 
it was imperative that the alkaline phosphatase detection system produced the optimum 
chromogenic result for the image analysis system. Four detection methods were evaluated for 
this purpose (see section 3.1). Also, each antibody required complete optimization. The 
technique for demonstrating AgNORs was also modified to produce the best overall result, as 
the high optical density of AgNOR dots is ideal for measurement using image analysis 
(Ruschoff, Plate, Contractor, Kern, Zimmermann and Thomas, 1990). 
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3. MATERIALS AND METHODS 
For a list of abbreviations see Appendix I. 
For a full list of materials and ordering information see Appendix II. 
All materials and the methods in which they were used were evaluated under Control Of 
Substances Hazardous to Health (C. O. S. H. H. ) guidelines at the outset of this study and 
reviewed, checked and approved by Health and Safety officers at regular intervals throughout. 
3.1 DEVELOPMENT OF ALKALINE PHOSPHATASE DETECTION SYSTEM 
In order to obtain the maximum information from the image analysis system, the optimum 
method of visualization of the alkaline phosphatase label needed to be determined. The four 
most widely used chromogens were evaluated for this reason. The methods used were - fast 
red method, hexazotised new fuchsin method, tetrazolium method and fast blue method, and 
these are outlined in detail below. These methods were evaluated on frozen rat small 
intestine as this contains very high levels of alkaline phosphatase. However, in order to 
preserve the tissue morphology the material required fixation prior to freezing (see below). 
Tissue fixation for alkaline phosphatase techniques 
- Take piece of tissue less than 5mm in size and place into paraformaldehyde solution at 
4°C 
- Leave at 4°C for 24 hours, then transfer to 5%o sucrose at 4°C 
- Leave overnight at 4°C, changing solution once 
- Cool tissue on pelcool or in cryostat until frozen 
- Store in liquid nitrogen for sectioning in cryostat at -20°C 
3.1.1 Method 1 (Fast red method) 
STOCK SOL UTION 
- Take 0.1 g Naphthol AS-MX phosphate (Sigma) and add 5m1 of dimethylformamide (DMF) 
- Dissolve well. Add 500m1 of distilled water 
- Add 500m1 of 0.2M Tris buffer at pH 8.4, then check solution pH is 8.4 
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SUBSTRATE SOLUTION 
- Take 25m1 of the stock solution 
- Add 15mg (0.015g) of Fast red violet LB salt (Sigma) 
- Add 25gl of 1M levamisole solution (Sigma) 
- Filter and use immediately 
3.1.2 Method 2 (Hexazotised new fuchsin method) 
HEXAZOTISED NEW FUCHSIN 
A- Take 0.5g of new fuchsin (BDH) and add 10m1 of 20% aqueous hydrochloric acid (HCI) 
Use mild heat with constant agitation (stirrer/hotplate) to dissolve 
Cool and filter the solution 
Store at 4°C (stable for months) 
B- Take Ig of sodium nitrite (BDH), add 25ml of distilled water, and dissolve 
Store at 4°C (stable for 1 week only) 
- Immediately before use mix together equal parts A and B 
- Leave to stand for approx 2 mins, and use within 30 min of synthesis 
SUBSTRATE SOLUTION 
- Take 25mg (0.025g) Naphthol AS-TR phosphate, sodium salt (Sigma) 
- Add 0.5m1 of DMF, and dissolve well 
- Add 50ml of 0.2M Tris-HCI buffer at pH 9.2 
- Add 0.5m1 of freshly hexazotised new fuchsin (see above) 
- Check pH is 9.2 (can adjust with 1M NaOH) 
- Filter before use 
3.1.3 Method 3 (Tetrazolium method) 
- Take 2.5mg of 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt (Sigma) 
- Add 10mg of tetranitro blue tetrazolium (Sigma) 
- Dissolve these in 0.7ml of DMF 
- Add I Oml of 0.2M Tris-HC1 buffer pH9.2 
- Mix and filter before use 
For this particular method these quantities only apply for small intestine 
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3.1.4 Method 4 (Fast blue method) 
STOCK SOL UTION 
- Add 10mg of Naphthol AS-MX phosphate (Sigma) to 0.25 ml DMF, dissolve well 
- Add 25m1 of Tris buffer pH 8.6 and 25m1 of distilled water 
- Mix together well and add 50mg of PVP (Sigma) 
SUBSTRATE SOLUTION 
- Add 25mg of fast blue RR salt (Sigma) to 50m1 of stock solution 
- Mix well 
- Check pH is 8.3, filter and use immediately 
The optimum incubation times were found to be 10-20 min for the fast red method, 20 min 
for the hexazotised new fuchsin method, 10 min for the tetrazolium method and fast blue 
method. Also, the optimum mounting media for these methods was investigated. Farrant's 
medium and D. P. X. caused the colour to fade quite quickly and D. P. X. actually affected the 
appearance of the chromogen, making it appear "grainy". PVA or Aquaperm (from 
Immunon) proved to be the optimum mounting media for all four methods. 
3.1.5 Method Selected 
After considering the colour produced and the ease of the technique to perform, the best 
overall method was found to be the fast red method. This technique produced a bright red 
colour (see figure 2), and the solutions required are relatively simple to prepare and can be 
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Figure 2: Chromogenic reaction produced using the alkaline phosphatase fast red detection 
system (method 1). The red colour indicates the site of alkaline phosphatase activity within 












Figure 3: Chromogenic reaction produced using the alkaline phosphatase hexazotised new 
fuchsin detection system (method 2). The red colour represents the site of alkaline 
phosphatase activity within rat small intestine. Magnification x250. 
The hexazotised new fuchsin method (figure 3) actually gave an even brighter red colour than 
the fast red method (figure 2) but the solutions used required more preparation time. So, this 
method would only really be useful in certain situations, such as for slides that are to be 
photographed. 
The tetrazolium method produced a very strong black colour at the site of alkaline 
phosphatase activity (see figure 4). The colour was very strong and developed very quickly, 
however, it could not be used on lung samples as it would be too easily confused with carbon 
deposits, which are prevalent in lung tissue, causing false positive results for 
immunocytochemistry. 
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The fast blue method produced a blue colour that was of a weaker intensity than the colours 
in the previous methods (see figure 5). This method could, however, prove useful as a second 
chromogen in a double immuno-staining method. 






Figure 4: Chromogenic reaction produced using the alkaline phosphatase tetrazolium 
detection system (method 3). The black colour represents the site of alkaline phosphatase 














Figure 5: Chromogenic reaction produced using the alkaline phosphatase fast blue detection 
system (method 4). The blue colour represents the site of alkaline phosphatase activity within 
rat small intestine. Magnification x250. 
3.2 DEVELOPMENT OF CELL MONOLAYER PREPARATION 
In histological sections the majority of cells are not whole, and this can reduce the accuracy of 
results obtained from the image analysis system. So, in order to maximize the quantitative 
information obtained a technique needed to be developed that would provide whole cells with 
minimal background contamination. The starting point for this work was a technique 
proposed by Van Driel Kulker et al in 1985, which was then modified for use with routinely 
processed tissue, as outlined below. 
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3.2.1 Preparation from unembedded tissue 
The tissue used for this part of the work was formalin fixed, but unembedded. The technique 
was developed first on normal rabbit lung and then on a human lung tumour. 
- Take 0.22g of tissue and cut into 4 pieces 
- Wash tissue in wash buffer (6.8% sucrose on 0.05M PBS) at least 3 times (once overnight) 
- Cut 1 piece of tissue and place in 0.05% trypsin solution (Difco), containing glass beads 
(Orme) 
- Incubate for 90 min, vortex mixing intermittently 
- Syringe suspension through capillary pipette 
- Filter solution through 100µm nylon gauze 
- Centrifuge suspension (2500 rpm for 5 min) and decant supernatant 
- Add 1 ml of carbowax (2% polyethylene glycol 1500 in 50% ethanol) 
- Break up cell clumps by adding glass beads and vortexing 
- Dilute solution 1: 2 with phosphate buffered saline (PBS) 
- Cytocentrifuge onto APES slides (1000 rpm for 15 min, using 500µ1 volume) 
- Fix in 95% ethanol for at least 30 min 
- Stain sections and mount in DPX 
Parameters Altered 
Enzyme used - trypsin, proteinase K, collagenase IV, protease XXIV (all from Sigma) 
Incubation times - 30 min, 60 min, 90 min, 120 min (for each enzyme) 
3.2.2 Preparation from paraffin embedded tissue 
Used human formalin-fixed, paraffin-embedded lung tumour tissue to develop the technique. 
- Cut 30µm section off block 
- Place in 2 changes of 3ml of xylene for 10 min 
- Place in 3ml of 100% alcohol for 10 min 
- Place in 3ml of 95% alcohol for 10 min 
- Place in 3m1 of 70% alcohol for 10 min 
- Place in 3ml of 50% alcohol for 10 min 
- Place in 3ml PBS for 10 min 
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- Centrifuge and decant supernatants to change solutions 
- Add 2m1 of 0.05% trypsin solution at 37°C 
- Incubate for 90 min with glass beads, vortexing the solution intermittently 
- Syringe suspension through capillary pipette 
- Filter the solution through 100µm nylon gauze (to remove beads and tissue) 
- Centrifuge suspension (2500 rpm for 5 min) and decant supernatant 
- Add 3m1 of PBS and syringe through capillary pipette. Repeat 
- Remove debris from cell solution (see 3.2.3) 
Parameters Altered 
Enzymes used - trypsin, proteinase K, protease XXIV, collagenase IV, trypsin-EDTA 
Enzyme concentrations - 0.05%, 0.1% 
Incubation time - 30 min, 60 min, 90 min, 120 min (for each enzyme and concentration) 
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Figure 6: Cell monolayer preparation before the removal of debris which can clearly be 
3.2.3 Removal of debris 
After finding the best overall technique for producing the monolayer there was still too much 
background debris for the image analyser to be effective, as the background "noise" would be 
too high. Three methods of debris removal were assessed (outlined below) 
A) Differential Centrifugation 
The first method tested was differential centrifugation using Optiprep (Nycomed) in a non- 
continuous gradient. This did not work. Next, was the use of a continuous gradient made 
from two very dense layers mixed in a gradient mixer (1.163 and 1.32 g/ml in saline). This 
was also unsuccessful. Eventually a gradient was found that worked which consisted of just 
very minimally diluted optiprep (1 layer), however, this was found to give unreproducible 
results. 
B) Membrane Filtration 
With equipment available at the Royal Liverpool University Hospital Trust cytology 
department tested the usefulness of a polycarbonate membrane of 5µm pore size (see below). 
All membranes were handled using tweezers to minimize contamination. 
- Filter sample through a membrane under negative pressure 
- Fix membrane in 95% ethanol for approximately 10 min 
- Clip membrane onto the slide (cell-side upward) 
- Stain with H&E and take slide to xylene 
- Invert membrane onto the slide and blot 
- Seal membrane edges using a stick dipped in chloroform and dry at 60°C 
- Dissolve membrane in chloroform (approximately 45 min) 
- Dip in xylene and mount using DPX 
Then tried using 12µm pore size polycarbonate membrane (CoStar UK Ltd) with a positive 
pressure system (syringe) and a pressure-fixation method of transferring the cells to a glass 
slide (Oud et a1,1984), which is outlined below: 
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- Place membrane onto filter holder with shiny side toward inlet 
- Draw 5ml PBS into syringe, attach to holder 
- Expel PBS through holder to wet the membrane 
- Draw sample into syringe and expel through holder 
- Draw up 5m1 of PBS and rinse membrane 
- Take membrane out of filter holder and place cell side down onto glass slide 
- Place sponge soaked in ethanol over membrane and apply pressure for 60 secs 
- Remove pressure and sponge and fix slide for further 30 min in ethanol 
- Stain, clear and mount as required 
The "cytoshuttle" from Cell-Path which employed the same principle as the above membrane 
filtration technique was also investigated, but to remove the cells from the filter it was 
claimed that only blotting was required. This method was found to give an extremely low 
cell yield and was therefore ruled out. 
C) Gauze Filtration 
Samples of 20µm and 30µm gauze mesh were obtained from Cell-Path for use in 2 different 
filtration methods outlined below. 
METHOD I 
- Fix gauze over top of filter funnel and apply sample 
- Invert gauze and elute cells by adding PBS 
- Take 500µl of solution and spin onto slide using cytospin 
- Fix, stain and mount as required 1, 
This method gave a low cell yield and was unreproducible 
METHOD 2 
- Cut 25mm circles from the gauze and place in filter holder 
- Draw PBS into syringe and run through holder to wet the gauze 
- Draw sample into syringe and expel through holder 
- Invert gauze in the holder (using tweezers) 
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- Draw up PBS and expel through holder and collect cells 
- As before, spin cells onto slide using cytospin 
- Fix, stain and mount as required 
Both the second filtration method and the polycarbonate membranes were found to remove 
the debris and leave an adequate number of cells for investigation. 
Figure 7: Cell monolayer preparation after the removal of debris by 20µm gauze filtration 
(case no -21/95). The difference after debris removal is quite clear as the tumour cells are 
now obviously isolated. Magnification x400 
3.2.4 Immunocytochemistry on cell monolayers 
For all immunocytochemistry on monolayers used PCNA, as this is a reliable, well known 
antibody that should have been positive on both the runt pig small intestine and lung tumour 
used. The monolayers were prepared as in section 3.2.2 and cleaned up as described in 3.2.3. 
For all the procedures the primary antibody was applied overnight at 4°C, the secondary 
antibody and the streptABC/AP were both applied for 2 hours each at RT. 
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Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking 1 min ; No antigen retrieval 
Concentration - 1: 50,1: 100,1: 150 
The antigen retrieval procedures removed the cells so when antigen retrieval was required the 
slides needed to be coated in LVN (as in section 3.13). This procedure was repeated a further 
4 times but no reaction was observed. 
There was the possibility that the long exposure to trypsin during the tissue digestion stage 
was destroying or altering the antigen, so an alternative was investigated. An ultrasonic 
cleaning bath was used to disaggregate the cells for the monolayer which was then used for 
PCNA immunostaining throughout. 
Parameters Altered 
Ultrasonic bath - 60 min, 90 min, 120 min, 180 min 
The sample was placed in PBS in water in the sonic bath and was mixed every 30 min. 
Removed after 120 min and solution filtered through 100µm gauze to remove tissue left. 
Immunostaining was still negative. 
Permeabilization solution was also tried on the slides before immunostaining. 
Permeabilization solution = 0.1% triton x-100 in 0.1% sodium citrate for 2 mins, 4°C 
Also tried 5 min and 10 min exposure, with microwaving and pressure cooking and without. 
Immunostaining still negative. 
The next alternative was to carry out all inununostaining and antigen retrieval in test tubes 
and only at the end put them onto slides. 
Parameters Altered 
Tried different forms of antigen retrieval on cells in test tube: 
Pressure cooking 1 min, pressure cooking 3 min 
microwaving 20 min / stand 20 min 
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trypsinization for 15 min at 37°C 
protease treatment for 5 min at 37°C 
Immunostaining results were still negative. 
TRYPSINIZATION 
Solution consists of 0.1% trypsin in TBS with 0.1% calcium chloride 
- Add calcium chloride to TBS and warm to exactly 37°C 
- Add trypsin when solution is 37°C 
- Treat sections (cells) for 5-15 min and wash 
PROTEASE TREATMENT 
Solution consists of 0.03g protease XXIV in 300ml TBS 
- Prewarm TBS to 37°C and add enzyme just prior to use 
- Treat sections (cells) for 1-10 min and wash 
As a final test to show once and for all that these cells just could not be immunostained a 
combination of enzymes with and without permeabilization solution was tried. 
Parameters Altered 
Trypsin for 20 min at 37°C 
Permeabilization solution for 2 min at 4°C, trypsin for 15 min at 37°C 
Protease for 15min 37°C 
Permeabilization solution for 2 min 4°C, protease for 10 min 3 7°C 
ALL RESULTS NEGATIVE FOR IMMUNOSTAINING 
Therefore, the study reverted back to using conventional histological serial sections in 
conjunction with image analysis. 
3.3 PROCEDURE FOR HAEMATOXYLIN AND EOSIN (H&E) STAINING 
All sections used were stained by H&E (Bancroft and Stevens, 1990) as this provides a 
picture of the general tissue morphology. 
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- Take sections to water 
- Place in Gadsdons haemalum for 5 min 
- Rinse in running tap water for 1 min 
- Place in I% acid-alcohol solution for 10 sees (check under microscope) 
- Rinse in running tap water for 2 min 
- Rinse in warm running tap water for 1 min 
- Place in Eosin solution for 5 min 
- Rinse briefly in running tap water 
- Dehydrate, clear and mount in DPX. 
(1% acid-alcohol = 1% conc HCl in 70% ethanol) 
3.4 PREPARATION FOR IMMUNOCYTOCHEMICAL METHODS 
Optimization of the immunocytochemical procedure is essential for both quantitative and 
subjective assessment of the antigen under investigation. This requires determining the 
optimum incubation time and temperature and the most appropriate form of antigen retrieval, 
using as a basis the recommendations provided by the supplier. One parameter is altered at a 
time and so the procedure has to be repeated several times before it is optimized. Due to the 
aggressive nature of the antigen retrieval techniques and the numerous washing steps required 
sections are often lost from slides, so now all slides used in immunocytochemistry are coated 
with 3- aminopropyltriethoxysilane (APES) solution (see below) which causes stronger 
adherence of the sections to the slide preventing them from floating off. The general 
procedure for the microwave oven and wet autoclave pretreatment (pressure cooking) forms 
of antigen retrieval are also given below. Trypsinisation as a form of antigen retrieval was 
tried but the results obtained from the other procedures were better and more reliable. When 
the sections used are very small (e. g. the needle biopsies used in this study) it is possible to 
draw around the sections using an immunocytochemistry pen (Dako) which forms a 
hydrophobic barrier, ensuring that the reagents applied remain on the sample. 
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3.4.1 Preparation of APES slides 
- Take clean slides to tap water 
- Transfer to hot, soapy water 
- Rinse very well in running tap water 
- Rinse in distilled water 
- Dry in slide dryer (approximately 30 min) 
- Transfer to pot of acetone, then drain 
- Dip in 2% APES solution (Sigma) in acetone 
- Allow to drain, but not fully dry (slide goes grainy) 
- Rinse in running tap water 
- Rinse in distilled water 
- Dry and return to clean slide box 
3.4.2 Antigen retrieval by microwave irradiation 
- Take sections to water 
- Place 500m1 of 0.01M citrate buffer pH 6.0 at room temperature into microwavable container 
- Put slides in plastic rack into container 
- Microwave on high power for 5.5 min 
- Place on simmer power for optimum time 
- Leave sections to stand in the cooling buffer for optimum time (if appropriate) 
- Put sections into room temperature tap water 
- Gently wash in running tap water for 3-5min 
- Put sections into tris-buffered saline (TBS) for immunocytochemistry 
3.4.3 Antigen retrieval by wet autoclave pre-treatment procedure (pressure cooking) 
- Place 1.51 of 0.01M citrate buffer pH 6.0 in a pressure cooker 
- Switch hotplate onto highest temperature 
- While buffer is boiling take sections to water 
- When the buffer is boiling add the sections in metal slide racks 
- Seal lid on correctly and put weight onto 1 dot position 
- When timer behind weight lifts start timing for, l min (time may differ) 
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- After 1 min switch weight to 2 dot position 
- Take off the heat and place in running cold water 
" Place sections in warm water (take care handling hot racks! ) 
- Transfer sections to TBS for immunocytochemistry 
FOR ALL IMMUNOCYTOCHEMICAL PROCEDURES 
StreptABC/AP solution = lml TBS +I Oµl solution A+I Oµl solution B 
Diluted Gadsdons Haemalum = Gadsdons haemalum diluted 1: 2 with distilled water 
All other dilutions required were made in TBS 
Each time the procedure is carried out control sections are included to check that all stages of 
the reaction are working correctly. The positive control is a section of known positive material, 
whereas the negative control is a known positive section that has had no primary antibody 
applied, just TBS. 11 
3.5 IMMUNOCYTOCHEMICAL PROCEDURE FOR MIB-1 ANTIGEN 
- Take sections to water 
- Carry out antigen retrieval for 1 min using 0.01 M citrate buffer pH 6.0 in a pressure cooker 
- Rinse sections in TBS 
- Apply normal rabbit serum (NRS) diluted 1: 3 for 10-15 min, room temperature (RT) 
- Drain slides and wipe around section -DO NOT WASH 
- Apply anti-Mib-1 (Immunotech cat-0505) at 1: 100 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply biotinylated rabbit anti-mouse (BRAM) secondary antibody at 1: 400 for 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 mins 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 mins 
- Make up and apply fast red substrate solution for 20 min, RT 
- Wash off using TBS "ý4 =a 
- Apply diluted Gadsdons haemalum for 10-20 secs 
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- Rinse slides in running tap water for approximately 2mins 
- Dip slides briefly into 1% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Runt pig small intestine 
Suppliers Recommendations 
1: 50 to 1: 100 1 hour RT ; Microwave 15min / stand 20 min 
Parameters Altered 
Antigen retrieval - Microwaving 20 min/stand 20 min, microwaving 10 min/standing 20 min 
Pressure cooking 1 min, pressure cooking 3min 
No antigen retrieval 
Concentration - 1: 75,1: 100,1: 150,1: 200,1: 250 
Temperature/Time - Ihour RT, overnight 4°C 
3.6 IMMUNOCYTOCHEMICAL PROCEDURE FOR NM23 ANTIGEN 
-'Take sections to water 
- Rinse slides in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-NM23 (Novocastra cat-NCL-NM23) at 1: 300, incubate overnight at 4°C 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT _ 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
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- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 mins 
- Dip slides briefly into 1% HC1 solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Human breast cancer 
Suppliers recommendations 
1: 100 to 1: 250 for 30 min RT ; No antigen retrieval 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, Microwaving 10 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
No antigen retrieval 
Concentration - 1: 150,1: 200,1: 250,1: 300 
Temperature / Time - 30 min RT, 60 min RT, overnight 4°C 
3.7 IMMUNOCYTOCHEMICAL PROCEDURE FOR C-MYC ANTIGEN 
- Take sections to water 
- Carry out antigen retrieval for 1 min using 0.01 M citrate buffer pH 6.0 in a pressure cooker 
- Rinse sections in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides - DO NOT WASH 
- Apply anti-C-MYC (Novocastra cat - NCL-CMYC) at 1: 150 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
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- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 min 
- Dip slides briefly into I% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Human colon cancer 
Suppliers recommendations 
1: 150 to 1: 250 1 hour RT ; May need antigen retrieval 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3 min 
Concentration - 1: 150,1: 200,1: 250,1: 300,1: 400 
3.8 IMMUNOCYTOCHEMICAL PROCEDURE FOR MDM-2 ANTIGEN 
- Take sections to water 
- Carry out antigen retrieval for 1 min using 0.01 M citrate buffer pH 6.0 in a pressure cooker 
- Rinse sections in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-MDM2 (Novocastra cat - NCLMDM2) at 1: 50 and incubate overnight at 4°C 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution and leave for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
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- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply Gadsdons haemalum solution for 10-20 secs 
- Rinse slides in running tap water for approximately 2 min 
- Dip slides briefly into 1% HC1 and return to tap water. 
- Dehydrate in 80% ethanol and mount using PVA 
CONTROL TISSUE - Human sarcoma 
Suppliers Recommendations 
1: 50 to 1: 100 overnight 4°C ; Pressure cook antigen retrieval for 1 min 0.01M citrate buffer 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
Concentration - 1: 40,1: 50,1: 75,1: 100,1: 150 
Temperature / Time -1 hour RT, overnight 4°C 
3.9 IMMUNOCYTOCHEMICAL PROCEDURE FOR BCL-2 ANTIGEN 
- Take sections to water 
- Carry out antigen retrieval for 1 min using 0.01M citrate buffer pH 6.0 in a pressure cooker 
- Rinse slides in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-BCL-2 (Dako cat - M887) at 1: 75 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
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- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 min 
- Dip slides briefly into 1% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Normal human tonsil 
Suppliers Recommendations 
1: 40 to 1: 80 1hour RT ; Microwaving 10 min / stand 20 min 
Parameters Altered 
Antigen retrieval - Microwaving 10 min / stand 20 min, Microwaving 20 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
Concentration - 1: 50,1: 75,1: 100,1: 150 
3.10 IMMUNOCYTOCHEMICAL PROCEDURE FOR P53 ANTIGEN (D07 clone) 
- Take sections to water 
- Carry out antigen retrieval for 1 min using 0.01 M citrate buffer pH 6.0 in a pressure cooker 
- Rinse slides in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides - DO NOT WASH 
- Apply anti-P53 (Dako cat - M7001) at 1: 100 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM at 1: 400 for minimum 30 min, RT 
- Make up ABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply ABC/AP solution for 30 min, RT 
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- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 mins 
- Dip slides briefly into 1% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Human non-small cell lung cancer 
Suppliers Recommendations 
1: 50 to 1: 1001 hour RT ; Microwaving 10 min / stand 20 min 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
Concentration - 1: 50,1: 100,1: 150,1: 200,1: 300 
3.11 IMMUNOCYTOCHEMICAL PROCEDURE FOR C-ERBB-2 MONOCLONAL 
- Take sections to water 
- Rinse sections in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around sections - DO NOT WASH 
- Apply C-ERBB-2 monoclonal antibody (Novocastra cat - NCLCB11) at 1: 40 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
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- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 mins 
- Dip slides briefly into 1% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA' 
CONTROL TISSUE - Human breast cancer 
Suppliers Recommendations 
1: 40 1 hour RT ; No antigen retrieval 
Parameters Altered 
Antigen retrieval - Microwaving 20 min/ stand 20 min, microwaving 10 min/ stand 20 min 
-Pressure cooking 1 min, pressure cooking 3min 
No antigen retrieval, 
Concentration - 1: 40,1: 50,1: 100 
3.12 IMMUNOCYTOCHEMICAL PROCEDURE FOR PCNA ANTIGEN (PC-10 epitope) 
- Take sections to water 
- Carry out antigen retrieval using 0.01 M citrate buffer pH 6.0 in microwave 20 min /stand 20 min 
- Rinse slides in TBS 
- Drain slides and apply NRS diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-PCNA (Dako cat - M879) at 1: 700 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
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- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 sees , 
- Rinse slides in running tap water for approximately 2 mins 
- Dip slides briefly into I% HCl and return to tap water 
- Dehydrate in 80% ethanol and mount using PVA 
CONTROL TISSUE - Runt pig small intestine 
Suppliers Recommendations 
1: 50 to 1: 100 1hour RT ; No antigen retrieval 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking I min, pressure cooking 3min 
No antigen retrieval 
Concentration - 1: 100,1: 200,1: 400,1: 500,1: 600,1: 700 
3.13 IMMUNOCYTOCHEMICAL PROCEDURE FOR C-ERBB-2 POLYCLONAL 
A polyclonal antibody is generally raised in a rabbit (unlike monoclonal antibodies which are 
raised in mice) so rabbit serum and rabbit secondary antibodies cannot be used due to cross- 
reactivity. For this particular polyclonal antibody swine serum and a swine secondary antibody 
were employed. 
- Take sections to water, 
- Carry out antigen retrieval for 1 min using 0.01M citrate buffer pH 6.0 in a pressure cooker 
- Rinse slides in TBS and then apply normal swine serum diluted 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply C-ERBB-2 polyclonal antibody (Dako cat - A485) at 1: 300 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
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- Apply secondary antibody (biotinylated swine anti-rabbit) at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse slides in running tap water for approximately 2 mins 
- Dip slides briefly into I% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount using PVA 
CONTROL TISSUE - Human breast cancer 
Suppliers Recommendations 
1: 100 to 1: 200 1 hour RT ; Microwaving 10 min / stand 20 min 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 10 mini stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
Concentration - 1: 100,1: 200,1: 300,1: 400 
3.14 IMMUNOCYTOCHEMICAL PROCEDURE FOR Retinoblastoma (RB) ANTIGEN 
Several problems were encountered in obtaining a reliable and reproducible protocol for this 
particular antigen. Different commercial antibodies were used with varying degrees of success, as 
well as different immunohistochemical detection systems and other technical modifications, as 
outlined below. 
NOVOCASTRA RBI 
The first RB antibody tried was from Novocastra (cat - NCL RB 1). 
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Suppliers Recommendations 
1: 50 overnight 4 °C ; No antigen retrieval 
Parameters Altered 
Antigen retrieval - Microwaving 20 min/ stand 20 min, microwaving 10 min / stand 20 min 
Pressure cooking 1 min, pressure cooking 3min 
No antigen retrieval 
Temperature / Time -1 hour RT, overnight 4°C 
Concentration - All 1: 50 (as should definitely work according to supplier) 
As all results obtained were negative Novocastra supplied a sample of a different batch of the 
same antibody, which was tested as listed below 
Parameters Altered 
Tried 1: 50, overnight 4°C, no antigen retrieval 
This procedure was used with the ABC/AP method (as used for the previous monoclonal 
antibodies) and the ABC/HRP method (given below) 
Also an NM23 control section was stained at the same time (see section 3.4) to control the other 
stages of the procedure. 
3.14.1 ABUMPImmunocytochemical Procedure 
- Take sections to absolute alcohol 
- Place sections in 3% hydrogen peroxide in 100% methanol for 12-15 min 
- Wash well in tap water 
- Drain slides and apply NRS diluted 1: 5 for 15-30 min 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-RB at 1: 50 and leave overnight at 4°C 
- Drain slides and wash in TB S, for 5-10 min 
- Apply BRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/HRP solution (in same way as ABC/AP) and leave to stand for 30min, RT 
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- Drain slides and wash in TBS for 5-10 min -. 1 _1 1 
-'Apply pre-mixed streptABC/HRP solution for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min - ', - , 
- Apply diaminobenzidine (DAB) solution for 10-15 min, RT 
- Wash off using TBS 
- Apply Gadsdons haemalum diluted 1: 2 for 1-2min 
- Rinse slides in running tap water for approximately 2 mins 
- Dehydrate, clear and mount in DPX 
DAB solution - Take a 0.01 g/ml frozen aliquot of 3-3'diaminobenzidine tetrachloride 
Add to 0.2m1 of 30% hydrogen peroxide when slightly defrosted 
Make up to 20m1 with TBS and filter onto sections 
CONTROL TISSUE - Human breast cancer -° 
Both the ABC/AP and the ABC/HRP methods failed to work for the RB antigen, but the actual 
procedure was working, as a positive reaction was obtained for the NM23 section. 
Another modification was using 3% bovine serum albumin (BSA) in place of the NRS 
The antibody was used at 1: 50 overnight 4°C, no antigen retrieval - No reaction 
A different secondary antibody (BRAM) was obtained from Vector Labs 
The antibody was used at 1: 50 overnight 4°C, no antigen retrieval - No reaction 
NOVOCASTRA RB 
Novocastra then sent a sample of their new rb clone to try (cat - NCL RB) 
Suppliers Recommendations 
1: 20 - 1: 50 30 min RT ; High temperature antigen retrieval 
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It was decided to try the alkaline phosphatase anti-alkaline phosphatase (APAAP) technique 
(described below) using both the RB 1 antibodies and the new RB clone, because for an unknown 
reason the results of the streptABC/AP technique were unreliable and unreproducible. 
RB1 - 1: 50 overnight 4°C, pressure cooking 1'min in 0.01M citrate buffer pH 6.0 
1: 50 overnight 4°C, pressure cooking 1 min 0.01M citrate solution pH 6.0 
This procedure was repeated for both the original RB 1 and the newer sample of RB 1. 
RB - 1: 40 1 hr RT, pressure cooking 1 min 0.01 M citrate buffer pH 6.0 
1: 40 1 hr RT, pressure cooking 1m in 0.01M citrate solution pH 6.0 
The APAAP procedure was found to work for the RB clone as described below. 
3.14.2 APAAP Immunocytochemical Procedure, 
- Take sections to water 
- Place slides in 0.01 M citrate solution pH 6.0 for 1 min in a pressure cooker 
- Rinse slides in TBS and then apply NRS diluted 1: 3 for 10-15 min 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-RB (Novocastra cat - NCL RB) at 1: 40 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply non-BRAM secondary antibody at 1: 50 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply APAAP solution at 1: 10 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TBS 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse in running tap water for approximately 2 mins 
- Dip briefly into I% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
However, the result obtained was not very strong, so the RB antibody was used in the strept 
ABC/AP procedure., , 
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Parameters Altered 
Antigen retrieval - Pressure cooking 1 min, pressure cooking 3 min 
Microwaving 20 min / stand 20 min, microwaving 10 min / stand 20 min 
Both citrate solution and citrate buffer were tried as antigen retrieval solutions 
Concentration - 1: 20,1: 40, -1: 75 
Temperature / Time - 30 min at RT, 60 min at RT 
CONCLUSION 
The results obtained were inconclusive even after repeating 3 times, as well as using the APAAP 
method with the same altered parameters as listed above. The outcome was that the antibody gave 
unreliable and inconsistent results, so another commercial clone was ordered from a different 
supplier. 
BIOGENEX RB 
An rb antibody sample was obtained from Biogenex that came prediluted to 1: 40, and was 
recommended to be microwaved for 15 min and to stand for 15 min. 
This was found to work using the streptABC/AP method and, after repeating several times, was 
found to give reliable and consistent results therefore this antibody was used for the study. 
3.14.3 Immunocytochemical Procedure Used For RB 
- Take sections to water . 
- Carry out antigen retrieval using 0.01 M citrate solution pH 6.0 for 1 min in a pressure cooker 
- Rinse slides in TBS 
- Drain slides and apply NRS diluted to 1: 3 for 10-15 min, RT 
- Drain slides and wipe around section - DO NOT WASH 
- Apply anti-RB (Biogenex cat - MU290-UC) at 1: 40 for 60 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply GRAM secondary antibody at 1: 400 for minimum 30 min, RT 
- Make up streptABC/AP solution and leave to stand for 30 min, RT 
- Drain slides and wash in TBS for 5-10 min 
- Apply pre-mixed streptABC/AP solution for 30 min, RT 
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- Drain slides and wash in TBS for 5-10 min 
- Apply fast red substrate solution for 20 min, RT 
- Wash off using TB S 
- Apply diluted Gadsdons haemalum for 10-20 secs 
- Rinse in running tap water for approximately 2 mins 
- Dip briefly into I% HCl solution and return to tap water 
- Dehydrate in 80% ethanol and mount in PVA 
CONTROL TISSUE - Human breast cancer 
Suppliers Recommendations 
1: 40,30 min, RT ; Antigen retrieval required 
Parameters Altered 
Antigen retrieval - Microwaving 20 min / stand 20 min, microwaving 15min / stand 15min 
Pressure cooking 1 min, pressure cooking 3min 
Concentration - 1: 40,1: 50,1: 75 
3.15 PROCEDURE FOR AgNOR STAINING 
All water used for this procedure was ultra pure water (to minimize contamination) 
- Take sections to water 
- Prepare 2% gelatine in 1% formic acid (AgNOR solution) 
- Prepare 10% aqueous silver nitrate solution 
- Mix AgNOR solution 1: 2 with silver nitrate solution 
- Apply to sections and incubate in the dark for 6 hrs, RT --- 
- Wash well in ultra-pure water 
- Dehydrate, clear and mount in DPX. 
CONTROL TISSUE - Pancreas - il 
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The actual AgNOR technique used requires determination by each individual laboratory, as 
different individuals tend to find that their own particular method works best for them, although 
the one-step method proposed by Ploton, Menager, Jeanneson, Himber, Pigeon and Adnet (1986) 
is the general method used. Various modifications were investigated to produce the optimal 
AgNOR technique for this study. These included changing the colloidal developer from gelatine 
to polyvinylpyrollidine (PVP) or polyethylene glycol (PEG) 20 000 (Rowlands, Crocker and 
Ayres, 1990), altering the concentrations of silver nitrate as well as the incubation temperature 
used, coating the slides and treating the slides in various ways after AgNOR staining. The 
optimum staining method decided upon after looking at these modifications is the one described 
above. 
Parameters Altered 
Silver nitrate concentration - 50%, 20%, 10%, 5% 
Incubation times - 30 min, 45 min, 60 min, 3 hrs, 6 hrs, overnight 
Incubation temperatures - RT, 45°C, 4°C 
Colloidal developers - gelatin, PVP, PEG 2000 
Post-AgNOR stain treatments - 1%gold chloride, 5% sodium thiosulphate, blue toning 
BLUE TONING AgNOR STAINING 
(Yekeler, Erel, Yumbul, Doymaz, Dogan, Ozercan and Iplikci, 1995) 
- Take sections to water 
- Carry out AgNOR staining as described above 
- Apply blue toning solution for maximum 10 secs 
- Wash in water 
- Dehydrate, clear and mount in DPX 
f 5ý 
BLUE TONING SOLUTION 
3Ommol/1 iron chloride plus l Immol/l potassium hexacyanoferrate (III) plus 33mmol/1 oxalic acid 
This modification still requires more work to ensure reproducibility and consistency, so it was not 
included as part of the AgNOR staining performed for this study. 
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APES slides were found to attract the deposition of silver grains, possibly due to the slight charge 
they have, in order to overcome this celloidin or low viscosity nitrocellulcose (LVN) were used to 
coat APES slides (see below). 
LVN COATING OF SLIDES 
- Dissolve approximately 25% LVN in a mixture of 50% diethyl ether - 50% absolute alcohol 
- Add slides to solution and then remove slowly and steadily 
- Leave slides to dry 
- When slides dry dip into 70% ethanol to set the coating 
- Stain slides (using the AgNOR technique) 
- When stained dissolve coating in the diethyl ether - alcohol mixture 
- When coating dissolved wash the slides in water 
Parameters Altered 
The concentration of the LVN solution required altering as no silver stain was able to get through 
the coating, as it was too thick. 
Tried - 75%, 50%, 25% of original strength. 
50% gave the best result but was not very reproducible. 
It was decided to just cut fresh sections onto chrome alum slides which showed no increase in 
silver deposit during the AgNOR reaction. 
CHROME ALUM COATING OF SLIDES 
- Clean slides in soapy water, as for APES slides 
- Dip slide into chrome alum solution 
(Dissolve 2g gelatin in 400m1 distilled water, when cool add 0.2g of chrome alum) 
- Dry slides and store at 4°C 
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Figure 8: Optimum AgNOR staining method on rat pancreas. The black dots represent the actual 
AgNORs which are easily distinguishable from the brown background. Magnification x400 
3.16 PROCEDURE FOR FEULGEN REACTION (Cold) 
(The cold Feulgen technique was developed by Elias JM, Conkling K and Makar M in 1972) 
- Take sections to water 
- Place sections in 5M HCl at RT for 45-60 min 
- Rinse in tap water 
- Rinse very well in distilled water 
- Place in Schiffs reagent at RT for 30 min 
- Rinse very well in distilled water 
- Counterstain using 0.1% aqueous light green solution for 2 mins, RT 
- Wash in water 
- Dehydrate, clear and mount in DPX. 
CONTROL TISSUE - Nasal polyp or spinal cord 
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Negative control (TCA removal of nucleic acids) 
- Take sections to water 
- Treat with 4% trichloroacetic acid (TCA) at exactly 90°C for 15min 
- Wash in water, carry out Feulgen reaction 
3.17 IMAGE ANALYSIS PROCEDURES 
All clinical material used within this study was supplied by Nottingham City Hospital and was 
identified only by case number (no names etc. were given) so that awareness of the clinical data 
could not influence the results, even subconsciously. The cases for subjective study were selected 
on the basis of being diagnosed as SCLC and having enough tissue within the block to cut 15 
serial sections (3µm each). For objective analysis the cases were selected on H&E for having 
reasonable morphological preservation for quantitation purposes. 
3.17.1 Image Analysis System 
There are various types of image analysis systems. The system used within this study acquired 
images from a Nikon Labophot-2 light microscope using a single chip JVC camera (TK- 1270) 
whose signal was captured by a DT 2871 frame grabber board. The image analysis software 
package was Foster-Findlay PC Image for Windows (version 1.64) used on a Dan 486DX2 50 PC. 
The system used RGB (red, green, blue) colour representation as this was found to be a more 
reliable system than HSI (hue, saturation, intensity) for the software and hardware used. For 
image analysis the signal received from the camera is digitized and stored in the digitizing board 
memory as a grey value. The digitization assigns a grey scale value between 0 and 255 where the 
value 0 represents no light and 255 represents maximum light, indicating that no absorbing 
structure is situated within the light path. Thresholding (or segmentation) is then used to 
discriminate between the object and the background, by setting a range of grey level values to 
select the pixels to be measured, which transposes the grey value image into a binary one, where 1 
represents the area occupied by cells and 0 represents the background. 
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3.17.2 Quantitation On Feulgen Slides } 
Each time the image analysis system is used the light microscope should be set up for optimal 
Kohler illumination. Firstly, a field was arbitrarily selected that contained a tumour nucleus, an 
image of this was then captured by the camera. The system was then calibrated for the 
magnification being used on the microscope which for all slides in this study was the x40 
objective. By a system of trial and error it was found that the most effective colour channel to 
work on for this stain was green. A threshold level was then set for the nucleus being investigated 
using the green channel only, after first sampling the image to give an approximation of the range 
of values to be used. This results in the formation of a binary image, which may be represented in 
either black or white (as required). The required measurements were then selected, which in this 
case were optical weight, detected area, and circularity. These measurements were made on 
individual objects (nuclei) by selecting them with the mouse pointer and "clicking" the left mouse 
button. The results were stored on the hard disk, with a floppy disk back-up (as a Foster Findlay 
internal format) and also saved as a text file for later use in spreadsheet packages. This procedure 
was repeated for at least 20 nuclei in each of the tumour samples and for a population of 
lymphocyte infiltration within a sample. It was necessary to select the magnification and 
parameters measured only at the beginning of each image analysis session. 
3.17.3 Quantitation For Nuclear Antigens (PCNA, Mibl, RB, PS3) 
As before, a field was containing a nucleus showing a positive reaction (red colour) was randomly 
selected and the image was captured, again on x40 magnification. Once again, the green channel 
was found to be the most effective, and the image was thresholded. The binary image colour was 
changed to black in order to enhance visualisation against the very pale background. Detected 
area (DA) and optical weight (OD) only were measured on at least 20 nuclei and saved as above, 
which allows the calculation of OD/DA per nucleus. This was all that was required for Rb and 
p53, although measurements were divided into central and edge of tumour results for Mib1, Mibc 
and Mibe respectively, although the central results appeared to represent the true reaction. As 
there is a problem with false positive reactions when using PCNA, it was decided to try setting a 
cut-off threshold point. This was set at 0-127on the green channel with cells above this value 
regarded as positive and those below classified as negative. 
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3.17.4 Quantitation For Cytoplasmic Antigens (CMYC, MDM2, BCL2, NM23, C-ERBB2) 
The microscope was set up for Kohler illumination, the x40 magnification objective was selected 
and a random image containing positive nuclei was captured. The threshold was set using the 
green channel so that all positive cells within the field were selected as a binary image, and the 
optical weight for the field was measured and stored. - The threshold was then increased so that all 
cells within the field were selected, the total object area was then measured. This procedure was 
performed on a total of 8 fields for each tumour and the average optical weight and object area 
calculated. 
For each antigen either nuclear or cytoplasmic only those sections that were subjectively positive 
(weak, moderate or strong) were measured objectively. This is because the image analysis system 
still always has a degree of bias i. e. the operator sets the thresholding levels, therefore it was 
decided that only those cases that had a red positive reaction detectable by the naked eye upon 
light microscopy would be considered as measurable. An example of a typical negative reaction 
is provided photographically in the results section. 
3.17.5 Quantitation OfAgNORs 
Generally AgNORs are counted using xl00 oil immersion on a light microscope. With this 
method the numbers of AgNOR dots are counted within a cell nucleus for an arbitrary number of 
fields, and the mean number of AgNORs per cell can be calculated. However, this does not take 
into account the actual size of the AgNORs, except as subjective observations that may be 
included. Several studies have previously advocated the use of image analysis systems to 
optimise and standardise AgNOR quantitation (Ruschoff et al, 1990 ; Derenzini and Trere, 1991). 
Within this study the image analysis system was used to calculate the AgNOR area per nucleus for 
100 nuclei in each tumour, a reference lymphocyte population was also measured. The results of 
9 cases plus the lymphocytes are given below (SD = standard deviation, CV = co-efficient of 
variation). 
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CASE NO. MEAN AgNOR AREA(µ2) SD CV 
10084/90 1.736 0.792 46% 
9136/89 2.443 0.881 36% 
15041/89 4.847 3.202 66% 
11928/90 1.632 0.834 51% 
15230/92 1.785 0.901 50% 
, 
1826/95 1.892 0.860 45% 
2896/91 3.431 2.518 73% 
4024/89 4.430 1.580 36% 
4580/92 1.589 0.847 53% 
LYMPHS 0.398 0.175 1 44%, 
Table 1: Results of AgNOR image analysis 
From these results it can be seen that the data obtained from image analysis of AgNORs was, in 
this case at least, virtually meaningless because of the huge variations within the tumours 
demonstrated by the high CV values. The large CV value in the lymphocyte population may be 
due to the fact that these were an infiltrate in one of the tumours, so some could have been 
proliferating while others were not giving rise to a variation in AgNOR values. Due to the large 
variations recorded in these randomly selected tumours it was decided to discontinue further 
AgNOR quantitation within this study. 
3.18 STATISTICAL ANALYSES 
Statistical investigations were carried out using the software Minitab (version 10.1)within 
Windows on a networked PC. 
3.18.1 Statistics on Subjective Data (172 cases) 
The only statistical test used on the subjective data was a simple correlation to check for 
significant correlations between pairs of biological markers. 
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3.18.2 Statistics on Objective Data 
Firstly, the objective data was considered using the biological markers only, for 51 cases. Again, 
a simple correlation was used to check for relationships between pairs of markers. Then only the 
31 cases that had survival data also available were considered, still in terms of the biological 
markers only. However, upon plotting a histogram of the survival data it was found to be very 
skewed so log10 of the survival data was used to overcome this problem. A best subset regression 
analysis (multiple regression) was carried out on these cases to identify the best combination of 
markers able to predict survival, up to a maximum of 5 parameters as too many would only cause 
further confusion. 
Then the results were tested using the biological markers in combination with data on the SCLC 
histological subtype (intermediate and oat cell), using a simple correlation analysis. A one-way 
analysis of variance (ANOVA) was carried out to determine if the 2 subtypes had different 
survival patterns. This was followed by a general multiple analysis of variance (MANOVA) to 
identify which of the biological markers have a statistically significant expression in either of the 
subtypes. 
The rest of clinical data was then brought into the analysis (treatment, age, sex) and again a simple 
correlation was carried out. A best subset regression was then performed once again to see if the 
clinical parameters had any influence upon predicting survival. FITS data was obtained from this, 
which is achieved by applying the regression equation generated to each case, thereby giving a 
value for predicted survival. A graph was then generated of predicted survival (FITS) against 
actual survival and any outliers were checked to see if they were patients whom no death date was 
available for (therefore they had to be considered as possibly still surviving). 
3.18.3 Comparative Statistics On Objective Plus Subjective Results (51 cases) 
The 51 cases that had been quantitated objectively for the biological markers were then compared 
against the same data available for these cases on subjective assessment. The subjective cases 
were scored on a scale of 0-3, with 0 being negative, I being weakly positive, 2 being moderately 
positive and 3 being strongly positive. This data was sorted into categories of 0-3 for each 
marker, the objective data was then placed alongside this and where there was enough data 
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available (i. e. more than 2 results available) the mean, SD and standard error (SE) was calculated 
for all the categories for each marker. The purpose of this was to illustrate the concordance 
between the two different methods of analysis. 
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4. RESULTS 
4.1 CELL MONOLAYER RESULTS 
After many different modifications (described in detail in section 3.2) a method was 
developed which isolated single whole SCLC cells from formalin-fixed, paraffin embedded 
material. This technique was then further modified to allow for the removal of background 
debris to facilitate quantitation. It was possible to stain the cells obtained with aH and E, but 
it was initially impossible to immunostain the cells obtained via the original technique 
developed. Therefore, the technique was further modified to increase the permeability of the 
cells to allow the dyes and antibodies to enter. However, no matter how many different 
modifications were attempted immunostaining was found to be impossible and so a serial 
histological sectioning approach was used. 
4.2 IMMUNOCYTOCHEMICAL RESULTS 
The optimised methods used for immunocytochemical staining and how they were 
determined are outlined in section 3. An example of a typical negative immunocytochemical 
reaction (blue) and a typical positive immunocytochemical reaction (red) for each of the 
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Figure 9: A typical negative immunocytochemical reaction on a SCLC (case no - 
9628/95). 
As this is a negative control section no primary antibody has been applied, so no red colour 
should be seen as there will be no reaction apart from non-specific 
background staining. The 
















Figure 10 :A tumour section showing a positive 
immunocytochemical reaction with the 
PCNA antibody (case no - 10669/93). The red colour 
is localized to the nucleus for this 
particular antigen. The red-stained positive cells are expressing 
this antigen and, according 









Figure 11 : Tumour section showing immunocytochemical positivity 
with the Mib-1 
antibody (case no - 5133/95). 
The Mib-1 antigen is localized to the nucleus which 
corresponds to the red nuclear staining seen. 
The positive cells are presumably proliferating 
as they express Mib-1 which 
is a marker of cell proliferation. Magnification x400. 
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Figure 12 :A tumour section showing a comparatively rare positive immunocytochemical 
reaction with the RB antibody (case no - 5133/95). The red positive reaction seen with this 
antibody is much weaker compared to that seen with the other antibodies used within this 
study. There were very few positive reactions as SCLC rarely expresses the RB protein. 
Magnification x400. 
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Figure 13 : Tumour section showing a positive nuclear immunocytochemical reaction with 
the P53 antibody DO-7, which identifies both wild type and mutant forms of the protein (case 
no - 5361/94). However the positive reaction seen will only represent mutant P53 as this the 
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Figure 14 : Tumour section showing the positive cytoplasmic staining reaction produced 
with the MDM-2 antibody (case no - 1826/95). The red reaction indicates the site of the 













Figure 15: Tumour section showing a positive immunocytochemical reaction with the C- 
MYC antibody (case no - 11221/9 1). The positive reaction can be seen to be cytoplasmic and 
variable in intensity. The actual site of the red reaction represents the site of the C-MYC 























Figure 16: Tumour section showing a positive immunocytochemical reaction with the 
NM23 antibody (case no - 11241/92). The red positive reaction produced by the NM23 
antibody is strong in comparison to the reaction products of other antibodies within this 
study. A definite pattern of protein expression is apparent with areas of red positivity seen 



















Figure 17: Tumour section showing a positive immunocytochemical reaction with the BCL2 
antibody (case no - 6958/95). This red reaction is once again cytoplasmic and is relatively 
weak, with some cells staining stronger than others. Magnification x400. 
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Figure 18 : Tumour section showing a positive immunocytochemical staining reaction with 
the C-ERBB-2 monoclonal antibody (case no - 10669/93). The red positive staining can be 








Figure 19 : Tumour section showing a positive immunocytochemical staining reaction with 
the C-ERBB-2 polyclonal antibody (case no - 6583/92). The red positive cytochemical 
reaction can be seen to be weak, as were all reactions with this antibody. However, it does 
appear less variable than the reaction seen with the monoclonal antibody to this antigen (see . 
Magnification x400. 
4.3 SUBJECTIVE RESULTS 
All 172 cases were initially assessed subjectively by light microscopy ( magnification x400). 
The cases were assessed as negative if no red reaction product was observed.. If a red 
reaction was noted cases were then graded on the strength of that reaction either as weakly, 
moderately or strongly positive. The photographic examples of positive 
immunocytochemical reactions in SCLC that are shown in section 4.2 are moderate or strong 
reactions (where possible). In order to compare the results obtained with those produced by 
other studies, a summary of the results obtained for each strength of reaction and for each 
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antigen was compiled from the somewhat lengthy table of full results which is provided in 
appendix N. These numerical results were also converted into percentages to make 
comparisons easier, and these may be seen in table 2 below. 
ANTIGEN -VE WK +VE MOD +VE ST +VE 
MIB 1 89/172 52% 38/172 22% 26/172 15% 19/172 11% 
PCNA 85/172 49% 30/172 17% 35/172 20% 22/172 13% 
P53 130/172 76% 17/172 10% 14/172 8% 11/172 6% 
RB 163/172 95% 5/172 3% 4/172 2% - - 
BCL2 132/172 77% 18/172 10% 13/172 8% 9/172 5% 
NM23 124/172 72% 30/172 17% 12/172 8% 6/172 3% 
MDM2 16/172 9% 26/172 15% 89/172 52% 41/172 24% 
C-ERBB-2p 159/172 92% 11/172 6% 2/172 2% - - 
CMYC 94/172 55% 45/172 26% 28/172 16% 5/172 3% 
C-ERBE-2m 142/172 82% 22/172 13% 7/172 4% 1/172 1% 
Table 2: A summary of the graded subjective results 
In order to compare the subjective results obtained with those from studies that did not grade 
strength of reaction, a more simplified table was compiled that merely gave percentages of 
positive and negative immunocytochemical reactions for each antigen studied. These overall 
subjective results in their simplest form are given in table 3 below. 
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ANTIGEN NEGATIVE POSITIVE 
MIB 1 52%- 48% 
PCNA 49% 51% 
P53 76% 24% 
RB 95% 5% 
BCL2 77% 23% 
NM23 72% 28% 
MDM2 9% 91% 
cerbB2 p 92% 8% 
CMYC 55% 45% 
cerbB2 m 82% 18% 
Table 3: A summary of the overall subjective results (full details in appendix V). 
4.4 OBJECTIVE RESULTS 
Of the 172 SCLC cases studied 51 cases were selected on the basis of morphological 
preservation for objective quantitation using digital image analysis. These results were 
compiled to illustrate the percentages of positive and negative results for each antigen studied 
objectively, rather than subjectively, and are given in table 4. For the objective results Mibl 
was assessed at the edge of the tumour section (Mibe) and at the centre (Mibc). Analysis 
deemed Mibc to be the true MibI result with Mibe appearing to be artefactual, possibly due to 
trauma incurred whilst removing the tissue sample. 
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ANTIGEN - VE + VE 
PCNA 19/51 37% 32/51 63% 
MIB e 39/51 76% 12/51 24% 
MIB c 24/51 47% 27/51 53% 
CMYC 25/51 49% 26/51 51% 
MDM2 4/51 8% 47/51 92% 
C-ERBB-2p 43/51 84% 8/51 16% 
BCL2 35/51 69% 16/51 31% 
NM23 26/51 51% 25/51 49% 
C-ERBB-2m 43/51 84% 8/51 16% 
P53 35/51 69% 16/51 1 
31% 
RB 48/51 94% 3/51 6% 
Table 4: A summary of objective results for the biological markers (full details available in 
appendix IV) 
4.5 STATISTICAL ANALYSIS RESULTS 
4. S. 1 Subjective Data 
All 172 cases available were assessed subjectively for each of the antigens studied and scored 
according to the reaction seen as either 0 (negative), I (weak positive), 2 (moderate positive), 
or 3 (strong positive). The results of a simple correlation test showed only 3 weakly negative 
correlations, the rest all being positive. The only statistically significant correlation seen 
(p<0.00) was between CMYC and C-ERBB-2 polyclonal, this was however a misleading 
result as graphically very little relationship was obvious. Also, it is possible that the 
polyclonal antibody is picking up something apart from the C-ERBB-2 antigen. Basically, 
the correlation results illustrate a high degree of inter-relationship between the markers i. e. 
when one marker is expressed others are also to a greater or lesser degree. 
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4.5.2 Objective Data 
4.5 2.1 BIOLOGICAL DATA 
A correlation test on all 51 results for the biological markers showed 15 weakly negative 
correlations, with the rest being positive. As before this shows all the markers to be 
correlated to some degree, with high inter-relationship between pairs of markers. The data 
used was then restricted to the 31 cases where survival data was available and multiple 
regression analysis was performed (best subset regression). This generated the best 
combination of markers (up to 5) that could be used to predict survival. 
For the available biological marker data the most statistically significant predictor was NM23, 
with ap value of 0.009 (same p value for the equation) and the regression equation being - 
log survival = 0.665 + 0.369nm23. The positive value preceding NM23 in the equation 
implies a possible positive prognostic role i. e. presence of NM23 is beneficial for patient 
survival. 
The best marker combination was for 5 markers, these being PCNA, Mibc (Mib 1), CMYC, 
NM23 and P53. The p values were - PCNA p<0.014, MibI p<0.023, CMYC p<0.081, NM23 
p<0.009, P53 p<0.201, and regression equation p value <0.007. The regression equation is 
given below - 
Log survival=0.625+O. 102 PCNA - 0.120 Mibl - 0.394 CMYC +0.406 NM23 + 0.0887 P53 
From the low p value of the equation (less than 0.05 is statistically significant) it can be seen 
that in combination these markers are highly statistically significant. The p values for the 
markers show NM23, MibI and PCNA to be statistically significant, and although strictly 
speaking CMYC is not significant alone it is only just outside significance, whereas P53 is 
well outside of this range. However, if P53 is removed from the combination the other 
markers lose significance, as does the combination of markers. It therefore seems likely that 
there is high inter-relationship between the markers in combination, so although P53 is not 
statistically significant alone it is important and necessary in combination. The contradicting 
signs mathematical signs on the regression equation for Mib and PCNA were investigated by 
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carrying out a separate regression analysis for each of the 2 markers. The actual values in the 
equation should not be taken as absolute as it may be the contrast between the markers that is 
the important factor. A comparison of the levels of these two markers in the 31 cases studied 
is given graphically in Figure 20, where it can be seen that 2 case were negative for PCNA 
but positive for MibI and 6 cases were positive for PCNA and negative for Mib1. As these 
antigens both represent markers of cellular proliferation the significance of this result is 
unclear, although the cases in question were immunostained several times in order to ensure 
that these results were genuine. 
The 51 cases used for objective analysis were selected randomly on the basis of 
morphological preservation and this was further reduced to 31 cases based on eliminating 
those on which survival and clinical information was unavailable, thereby eliminating bias. 
However, this presented a problem for the analysis of MDM2 protein as only 2 negative cases 
were included in the 31 objective cases studied. Therefore, the data on this marker is skewed 
and it will never achieve statistical significance in this study. 
4.5.2.2 BIOLOGICAL MARKERS IN HISTOLOGICAL SUBTYPES 
The same 31 cases were then looked at in combination with data on the tumour histological 
subtype (either intermediate or oat cell). A one-way ANOVA was carried out to illustrate that 
the two different subtypes had definitely different survival patterns, with oat cell having a 
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Source DF SS MS Fp 
hist 1 1.058 1.058 3.92 0.057 
Error 29 7.817 0.270 
Total 30 8.875 
Level N Mean StDev --+---------+---------+---------+---- 
0 24 0.7706 0.5514 (-------*------) 
171.2124 0.3708 (------------ * ------------) 
--+---------+---------+---------+---- 
Pooled StDev = 0.5192 0.60 0.90 1.20 1.50 
Figure 21: One-way ANOVA of histological subtypes against log survival 
A general MANOVA analysis was then carried out to identify any of the biological markers 
which had a difference in expression within the 2 subtypes. This identified 4 markers - 
Mibl, P53, NM23 and BCL-2 as having a difference in expression. These markers were then 
included in ANOVA analysis for further illustration (see below). The p values were MibI 
p<0.017, P53 p<0.002, BCL2 p<0.004 and NM23 p<0.000. For NM23 all intermediate types 
have higher levels of this protein than the 9/24 positive oat cell types. For BCL-2 the 5/7 
positive intermediate types have higher levels of this protein than the 6/24 positive oat cell 
types. For P53, generally the 6/7 positive intermediate types show higher levels of protein 
expression than the 5/24 positive oat cell types. For Mib1 (Mibc) the 5/7 positive 
intermediate types express higher levels of antigen than the 9/24 positive oat cell types. The 
full ANOVA data is shown below. 
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Source DF SS MS Fp 
hist 1 24.42 24.42 11.62 0.002 
Error 29 60.96 2.10 
Total 30 85.38 
Level N Mean StDev ----------+---------+--------- +------ 
0 24 0.687 1.389 (----*---) 
--------- 172.810 1.664 (-------*---------) 
---------------------------------------- 
Pooled StDev = 1.450 1.2 2.4 3.6 
Figure 22 : One-Way ANOVA for P53 in Histological Subtypes 
Source DF SS MS Fp 
hist 1 8.066 8.066 41.69 0.000 
Error 29 5.611 0.193 
Total 30 13.678 
Level N Mean StDev ---------+---------+---------+------- 
0 24 0.2821 0.4286 (---*--) 
171.5021 0.4807 (------*------) 
---------+---------+---------+------- 
Pooled StDev = 0.4399 0.50 1.00 1.50 
Figure 23 : One-Way ANOVA for NM23 in Histological Subtypes 
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Source DF SS MS Fp 
hist 1 2.106 2.106 9.65 0.004 
Error 29 6.329 0.218 
Total 30 8.435 
Level N Mean StDev ----------+---------+---------+------ 
0 24 0.2087 0.3896 (-----*-___) 
170.8322 0.6877 (----------*---------) 
----------+---------+---------+------ 
Pooled StDev = 0.4672 0.35 0.70 1.05 
Figure 24 : One-Way ANOVA for BCL-2 in Histological Subtypes 
Source DF SS 
hist 1 29.01 
Error 29 131.28 
Total 30 160.29 
MS Fp 
29.01 6.41 0.017 
4.53 
Level N Mean StDev -------+---------+---------+--------- 
0 24 1.441 1.923 (----- * -----) 
173.755 2.777 (----------*----------) 
-------+---------+---------+--------- 
Pooled StDev = 2.128 1.5 3.0 4.5 
Figure 25: One-Way ANOVA for Mibl in Histological Subtypes 
Simple correlation analysis showed a high correlation (0.768) between NM23 and 
histological subtype (p<0.000), which just backs up the information already shown by 
ANOVA and MANOVA analyses. A high correlation was seen between C-ERBB-2 
monoclonal and Mibe (0.641), but this was purely coincidence as there were only 4 positive 
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C-ERBB-2 results and 6 positive Mibe results. A similar correlation (0.649) was seen with 
RB and Mibe, but as there were only 2 positive RB results this was not considered significant. 
Another correlation was shown between P53 and Mibc (Mib1) (0.632) with ap value of 
0.000, and this was reflected by the inter-relationship apparent in the best subset regression, 
as when P53 is removed from the combination Mibl loses statistical significance. 
4.5.2.3 BIOLOGICAL DATA PLUS CLINICAL DATA 
A simple correlation test provided no new information, only that there is more positive than 
negative correlations and everything is related to some degree. When predicting survival 
histology was not statistically significant as a combination of biological markers had a higher 
significance i. e. there was a stronger correlation between biological markers and survival than 
between histological subtype and survival. As before multiple regression analysis was 
performed as best subset regression (up to a combination of 5 markers). NM23 was still the 
most statistically significant single predictor (same equation and p values as previously). 
However, once the number of factors increases above one NM23 loses significance and only 
appears in the second best combinations. The best combination of was found to be PCNA, 
Mibc (Mibl), P53, chemotherapy, and radiotherapy. The p values were - PCNA p<0.002, 
Mibl p<0.003, P53 p<0.01, chemo p<0.002, radio p<0.009 and equation p<0.000. 
The regression equation generated is shown below : 
Log survival = 0.151 + 0.115 PCNA + 0.699 chemo + 0.403 radio - 0.135 MibI + 0.154 P53 
As before it is likely to be relative levels that are important rather than the actual values given 
in the equation. The only possible negative prognostic factor is Mib1, which is still showing 
a contradictory prognostic role to PCNA. This time P53 is significant, although still to a 
lesser degree than the other factors in the combination. The results of the 2 treatment factors 
are as expected i. e. patient has a good prognosis if they have received chemotherapy or 
radiotherapy. In view of this the preferred combination to quote would be the biological 
markers only, as this can provide an prediction of survival based on the biology of the tumour 
at diagnosis before treatment has commenced. The relative levels of the markers in the best 
combination are demonstrated graphically in figure 26. As it can be seen not all markers are 
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expressed in each case which may reflect the inherent heterogeneous nature of all human 
tumours. 
FITS data was also collected during multiple regression analysis, this is generated by applying 
the regression equation to each tumour case and getting a value for predicted survival. This 
FITS data was then plotted against actual survival (Figure 27) to see if the relationship 
between the two was as close as expected. The outlying values were examined to see if they 
were caused by the "censored" data i. e. the survival data used where a death date was not 
available for the patient so the survival data used was the number of months that they were 
recorded to have survived, or where the patient is still alive. 
4.5.3 Comparison of Subjective and Objective Data 
The subjective results were grouped as 0,1,2,3 along with the objective data. The objective 
mean, standard deviation and standard error were then calculated for each group per antigen 
(table of these results in appendix ... ). Basically this showed that there was good agreement 
between the two types of result in that the objective results showed an increase going from 0 
to 3. CMYC was the only antigen that showed a decrease from 1 to 2. Although for RB and 
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5. DISCUSSION 
5.1 CELL PROLIFERATION 
The growth rate of a given tumour depends upon two main factors, these being the cell 
proliferation rate and the cell death rate. If the cell proliferation rate exceeds the cell death 
rate then the tumour will continually expand, so information on this parameter has long been 
regarded as highly useful by clinicians. Several methods are available for determining the 
cell proliferation state of a given tumour at a particular time. These include mitotic index, 
BrdU incorporation, thymidine labelling index, flow cytometry and immunocytochemistry 
(all described in further detail in chapter 1). The material available for this study was archival 
which ruled out the use of BrdU and thymidine, as these require the use of fresh tissue. The 
mitotic index is an extremely subjective and controversial technique. Flow cytometry also 
measures non-neoplastic cells and takes no account of tumour heterogeneity. 
Innnunocytochemistry was therefore the method of choice for this study. 
5.1. I PCNA 
Proliferating cell nuclear antigen (PCNA) was first identified in 1978 (Miyachi, Fritzler and 
Tan) and is a 36kD molecule that is highly conserved in evolution. PCNA functions as a co- 
factor for DNA polymerase S in both S phase and DNA synthesis associated with DNA 
repair. The PCNA molecule has a long half-life (approximately 20 hours), therefore, on exit 
from M phase cells will still have detectable levels of PCNA. Various anti-PCNA antibodies 
are available, and PC 10 was the one selected for this study due to the fact that it identifies the 
epitope most resistant to formalin fixation, and is also the most widely used. 
Although PCNA is widely recognized as a marker of cell proliferation, several studies have 
suggested that caution be used when interpreting results (Coltrera, Skelly and Gown, 1993). 
This is mainly due to the false positive results caused by the expression of the PCNA 
molecule in non-cycling cells due to it's long half-life. Other studies have also found a loss 
of PCNA immunoreactivity upon prolonged exposure to formaldehyde (Rowlands, Brown, 
Barber and Jones, 1991 ; Leong, Milios and Tang, 1993). In 1993 Fujii, Motoi, Saeki, Aoe 
and Moriwaki found PCNA to be of prognostic significance in NSCLC, although they also 
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noted a great heterogeneity of PCNA expression. Ishida, Kaneko, Akazawa, Tateishi, Sugio 
and Sugimachi (1993) also found that NSCLC with a high proliferation index, as assessed by 
PCNA to have a poor prognosis. 
When the results generated by this study were analysed the role of PCNA as a possible 
indicator of survival was found to be closely linked to the expression of four other antigens. 
5.1.2 Mib-1(Ki-67) 
Ki67 is an IgG, class murine monoclonal antibody raised against a crude nuclear fraction of 
the Hodgkin's disease derived cell line L428 (Brown and Gatter, 1990), and was first 
identified in 1983 by Gerdes et al. The Ki67 antibody reacts with a nuclear non-histone 
protein doublet of molecular weight 395 and 345 kD, present in all parts of the cell cycle (G,, 
S, G2 and M) except Go (Sawhney and Hall, 1992). The Mib1 antibody was produced to 
identify the Ki67 antigen in routinely processed tissue, as the Ki67 antibody was originally 
only intended for use on frozen sections. Several studies have subsequently shown Mib-1 to 
be true Ki67 equivalent (Cattoretti et al, 1992 ; Cuevas et al, 1993). It has also been shown 
that Mib- I staining correlates with semi-conservative DNA synthesis, rather than excision- 
repair DNA synthesis (McCormick et al, 1993). 
SCLC has been found to have a high Ki67/Mib-1 labelling index (Tungekar, Gatter, Dunnill 
and Mason, 1991). A study on neuroendocrine lung cancers using image analysis with Mib-1 
immunostaining, found that Mib-1 may be able to identify subgroups of lung cancer (Bohm, 
Koch, Gais, Jutting, Prauer and Hofler, 1996). Mib-1 has been verified as a reliable marker 
for the assessment of cell proliferation (Querzoli, Albonico, Ferretti, Rinaldi, Magri, Indelli 
and Nenci, 1996). There is also evidence that Mib-1 staining may be useful prognostically 
(Gee, Douglas-Jones, Hepburn, Sharma, McClelland, Ellis and Nicholson, 1995). 
The results of this study indicate that Mib1could be possibly useful in predicting survival in 
combination with other markers. There was also a difference in expression between SCLC 
histological subtypes, in that intermediate cell type expressed relatively higher levels of Mib 1 
than the oat cell types. 
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S. 1.3 Ploidy 
For this study ploidy was determined on the basis of the cold Feulgen stain for DNA, which 
was measured using digital image analysis. This showed the majority of tumours to be 
diploid and when it was employed as a parameter within the statistical analysis it was found 
to have very little significance. Full results are given in Appendix V. 
5.2 ONCOGENES 
5.2.1 CMYC 
The myc family of protooncogenes encode nuclear proteins that have DNA binding properties 
and are believed to be involved in transcriptional regulation. The three best characterized 
members of this family are C-myc, N-myc and L-myc. C-myc is the cellular homologue of 
the avian retrovirus oncogene v-myc. Amplification and overexpression of the N and L-myc 
genes have been described in SCLC but were not consistent with any morphologic, biological 
or clinical features, unlike c-myc (Gazdar, 1992). Only one member of the myc gene family 
is amplified in any given tumour. Amplification of myc genes is much less common in 
NSCLC compared to SCLC (Kern and Filderman, 1993). C-myc has been implicated to 
participate in DNA replication by influencing the initiation of DNA synthesis. As well as it's 
role in cell transformation, differentiation and cell cycle progression, c-myc also is also 
involved in some forms of apoptosis. Several studies have also shown that the oncogene bcl- 
2 (see section 5.2.4) can prevent c-myc induced apoptosis (Evan et al, 1992 ; Fanidi et at, 
1992). One study found there to be no correlation between the degree of myc gene 
amplification in primary tumours and survival time, and found myc amplification more 
frequent in patients who have undergone chemotherapy (Anderson and Spandidos, 1993). 
The results of this study did not highlight any significant association between C-MYC and 
BCL-2 protein expression in SCLC. Although the relative levels of these two proteins, as 
assessed quantitatively was similar, and much lower than the majority of the other markers 
studied. However, CMYC was found to be able to predict survival time in patients in 
combination with several other markers. 
94 
5.2.2 MDM-2 
Mdm-2 is found on chromosome 12 and produces a 90kD protein that forms a complex with 
mutant and wild type p53, suppressing it's trans-activation function. The mdm-2 gene has 
been reported to be amplified in sarcomas. MDM-2 has also been shown to interact with the 
RB protein, and to inhibit the Rb growth regulatory function (Xiao et al, 1995). Wild type 
P53 induces MDM-2 expression in response to DNA damage while over-expression of 
MDM-2 inhibits the ability of wild type P53 to stimulate the expression of target genes. 
Regulation of MDM-2 expression by P53 represents a potential feedback control of P53 
function. Analysis of MDM-2 and P53 in sarcomas indicates one or other to be mutated in 
70% of tumours. 
Analysis of the results of this study showed no significant association between MDM-2 and 
P53 protein expression. However, for both the subjective and objective data less than 10% of 
cases were negative for MDM-2, and of the 31 cases used for statistical analysis only 2 
MDM-2 negative results were included. The imbalance in this data means that, in this study 
at least, MDM-2 will never be of any statistical significance. 
5.2.3 C-ERBB-2 
The neu oncogene was first identified in rats (Schechter et al, 1985), whilst the human 
equivalent was independently cloned from a cDNA library and called HER-2 (Coussens et al, 
1985). However, after the gene was cloned from genomic DNA it was designated c-erbB-2 
(Semba et al, 1985). c-erbB-2 gene sequence and protein product (p 185) are closely related 
to the epidermal growth factor receptor (EGFR), and show an overall homology of 50%. The 
gene has been mapped to chromosome 17g21, also, the p185 protein belongs to class I of the 
superfamily of tyrosine kinase receptor molecules. 
Amplification or overexpression of the c-erbB-2 gene has been found to be a negative 
prognostic factor in breast cancers (Gazdar, 1992 ; DePotter, 1994). Yokota, Yamamoto, 
Tayashima, Terada, Sugimura, Battifora and Cline (1986) carried out a study of c-erbb-2 
amplification in a range of tumour types, and found amplification to be specific to 
adenocarcinomas, inclusive of lung tumours. Amplification of c-erbB-2 gene has been 
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observed in 1540% of breast cancers and 30% of ovarian cancers, with high levels of protein 
expression linked to shortened survival and disease free interval, as well as lymph node 
metastasis. Also, C-ERBB-2 protein expression has been identified as a negative prognostic 
factor in NSCLC (Kern, Schwartz, Nordberg, Weiner, Greene, Torney and Robinson, 1990). 
Further data was provided to back up this study, and reported the expression of the C-ERBB- 
2 protein to carry important negative prognostic information in lung adenocarcinomas (Kern 
and Filderman, 1993). A study in 1992 found approximately 60% of NSCLC to express C- 
ERBB-2 protein but noted an absence of expression in SCLC (Shi, Imam, Young and Cote, 
1992). These results were verified by Schneider et al (1992) who found absence of c-erbB-2 
mRNA and protein in SCLC, and suggested this as possibly being unique and maybe useful in 
a diagnostic sense. A direct concordance between c-erbB-2 gene amplification and increased 
protein expression was demonstrated by Venter, Tuzi, Kumar and Gullick in 1987. 
Statistical analyses of the results generated by this study found no correlations between the C- 
ERBB-2 protein and any of the other markers used with either the polyclonal or monoclonal 
antibody. As a comparison of the two antibodies the results were as expected in that the 
monoclonal antibody was more sensitive than the polyclonal antibody i. e. showed a higher 
level of positivity. Although the number of cases used for the objective study were 
approximately equal. 
5.2.4 BCL-2 
The bcl-2 gene was first identified at the chromosomal breakpoint of the t (14; 18) 
translocation in follicular lymphomas. In this translocation it is brought under the control of 
the promoter of the Ig heavy chain gene, leading to dysregulation of the gene product. High 
levels and aberrant patterns of BCL-2 protein expression have been reported in a wide variety 
of human cancers including colorectal, renal, neuroblastoma, non-Hodgkin's lymphomas and 
chronic and acute leukaemias (Reed, 1995). Immunolocalization studies have shown BCL-2 
to be an inner mitochondrial membrane protein of molecular mass 25 kD (Hockenbery et al, 
1990). BCL-2 expression inhibits cell death but does not enhance cell proliferation. BCL-2 
has also been implicated in the regulation of intracellular calcium distribution, as well as an 
antioxidant role. Some studies in vivo have shown that levels of P53 in breast cancer are 
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inversely related to expression of bcl-2 (Lu et al, 1996). Haldar, Negrini, Manne, Sabbioni 
and Croce (1994) also found an inverse correlation between the expression of BCL-2 and 
mutant P53 protein in breast cancer cells, suggesting that P53-induced apoptosis may be due 
to the down-regulation of the BCL-2 protein. Vaux, Cory and Adams (1988) showed that 
BCL-2 co-operates with C-MYC in cell transformation. 
Pezzella et al (1993) showed 20% of NSCLC to be positive for BCL-2 protein (on 
immunocytochemistry) and that these tumours had a better clinical outcome. They also 
demonstrated absence of BCL-2 protein expression in undifferentiated cells of the normal 
bronchial epithelium. Fontanini et al (1995) found a high level of BCL-2 positivity in 
NSCLC (mainly squamous cell carcinomas) at 67%, but agreed with Pezzella et al that BCL- 
2 overexpression seems able to induce a less aggressive phenotype. They demonstrated an 
inverse relationship between P53 and BCL-2 protein expression, and found no relationship to 
cell proliferation. Also, loss of BCL-2 expression was shown to be associated with shorter 
overall survival and metastatic development in this tumour type. High expression of BCL-2 
gene has been shown in SCLC cell lines, and the same study also demonstrated that BCL-2 
and C-MYC expression does not always occur together (Ikegaki et al, 1994). A study by 
Ben-Ezra, Kornstein, Grimes and Krystal (1994) showed a high level of BCL-2 protein 
expression in SCLC (65%). Yan et al (1996) suggested that BCL-2 expression is involved in 
the relatively early phases of SCLC tumorigenesis, due to the high level of positivity recorded 
(93%). They also suggest that expression of the BCL-2 protein in SCLC is not due to 
dysregulation of the protein but that it is a succeeding property directly derived from the 
SCLC progenitor cells. They found no correlation between BCL-2 and P53 expression as 
well as reporting BCL-2 expression to be of no use as a prognostic marker. No correlation 
between P53 and BCL-2 protein expression was reported by Walker et al (1995a) when they 
examined a series of lung cancers (only included 1 SCLC). A large study (60 cases) of BCL- 
2 protein expression in SCLC by immunocytochemistry found 90% to be BCL-2 positive, and 
suggested that this could be related to the theory that BCL-2 protein expression correlates 
with neuroendocrine differentiation (Jiang et al, 1995). A further study concluded that BCL- 
2 protein expression is differentially regulated in lung cancer histological types and may be 
closely related to neuroendocrine differentiation. The study involved carried out BCL-2 
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immunocytochemistry on 111 SCLC and found 104 to be positive for BCL-2 protein (Jiang et 
al, 1996). An inverse relationship between P53 and BCL-2 protein expression has also been 
demonstrated in colon cancers (Watson, Merritt, Jones, Askew, Anderson, Becciolini, Balzi, 
Potten and Hickman, 1996). 
The results of this study did not indicate any relationship between BCL-2 and any other 
marker, including P53 and CMYC. However, the levels of BCL-2 and P53 protein 
expression were almost identical, but CMYC was positive in many more cases. It was shown 
that BCL-2 protein was expressed at higher levels in intermediate type, than in oat cell type. 
This agrees with the findings of Pezzella et al and Fontanini eta! who found BCL-2 
overexpression to induce a less aggressive phenotype in NSCLC, as this study found a higher 
level of BCL-2 protein positivity in the less aggressive intermediate cell type compared to the 
more aggressive oat cell type. Previous studies which reported high levels of BCL-2 protein 
in SCLC did not comment on any differences in expression between histological subtypes of 
SCLC. 
5.3 TUMOUR SUPPRESSOR GENES 
5.3.1 PS3 
The p53 gene was first identified in 1979 (Lane and Crawford) by it's ability to bind the 
SV40 large tumour (T) antigen, and was subsequently reported in non-virally transformed 
cells. The gene is located on chromosome 17p13 and encodes a 53 kD nuclear 
phosphoprotein. Normal (wild type) P53 protein is always nuclear and has a short half-life so 
it doesn't accumulate, whereas mutant P53 protein may be found in both the nucleus and 
cytoplasm and has a longer half-life making it detectable by immunocytochemistry. Over 
90% of p53 mutations are missense mutations that change the identity of an amino acid. This 
can alter the conformation and increase the stability of the p53 protein and can indirectly alter 
the sequence-specific binding and transcription factor activity (Harris, 1993). P53 protein 
alterations due to missense mutations and loss of P53 protein by nonsense or frameshift 
mutations provide a selective advantage for clonal expansion of preneoplastic and neoplastic 
cells. Studies indicate that P53 protein is involved in gene transcription, DNA synthesis and 
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repair, genomic plasticity and programmed cell death. Abnormalities of the p53 gene or 
protein can be detected by fluorescent in situ hybridisation (FISH), restriction fragment length 
polymorphism (RFLP) analysis, sequencing of mutated exons, single strand conformational 
polymorphism (SSCP) analysis and immunocytochemistry. However, immunocytochemistry 
is of no use for detecting mutations which cause deletion or truncation of the protein, rather 
than accumulation. The predominant mutation seen in lung cancers is a G: C to T: A 
transversion (Mazur and Gluckman, 1988). 
BCL-2 has been shown to block P53-dependent apoptosis, but as it doesn't alter P53 levels or 
localization it is likely that it acts downstream of p53 by suppressing p53 dependent and 
independent pathways (Chiou, Rao and White, 1994). In fact, a reciprocal expression of 
BCL-2 and P53 protein expression has been shown in breast cancer (Haldar et al, 1994). 
Cells that co-express BCL-2 and C-MYC overcome P53-induced growth inhibition, possibly 
by exclusion of P53 from the nucleus during a critical period in G, (Ryan et al, 1994). p53 
mutations have been shown to be involved in 40-70% of colon cancers, 50% of lung cancers, 
10-65% of liver cancers, 30-60% of stomach cancers, 40-60% of ovarian cancers and 90% of 
cervical cancers, as well as bladder cancer, breast cancer, brain cancer, leukaemias, 
lymphomas and melanomas (Hager and Rogers, 1997). 
An increase in P53 protein has been demonstrated in SCLC, but shown not to occur in 
carcinoids (Iggo et al, 1990). In 1992 Sameshima, Matsuno, Hirohashi, Shimosato, 
Mizoguchi, Sugimura, Terada and Yokota demonstrated p53 gene alterations in over 80% of 
SCLC and found these to occur early in SCLC development, and these results were echoed by 
D'Amico, Carbone, Mitsudomi, Nau, Fedorko, Russell, Johnson, Buchhagen, Bodner, Phelps, 
Gazdar and Minna (1992). Whereas P53 protein mutations were shown in 70% of SCLC 
(Miller et al, 1992). Several studies have shown a general level of P53 protein positivity in 
lung cancers to be approximately 50% (McLaren et al 1992 ; Brambilla et al, 1993). In 1992 
Quinlan, Davidson, Summers, Warden and Doshi showed a strong correlation between P53 
accumulation and poor survival in NSCLC. Several studies have shown that P53 
immunostaining predicts for a favourable clinical prognosis in NSCLC, but that it is also 
independent of stage and histology (Passlick, Izbicki, Reithmuller and Panteller, 1994 ; Volm 
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and Mattem, 1994 ; Lee, 1995). P53 is also quoted as an independent prognostic factor in 
prostate cancer (Shurbaji, Kalbfleisch and Thurmond, 1995). Fontanini et al (1994) further 
found p53 alterations able to confer a more aggressive phenotype in NSCLC. 
Deb et al (1992) demonstrated that P53 protein expression is higher in non-oat cell SCLC 
than in other lung cancer histological types. They also noted a correlation between PCNA 
and P53 protein expression, which could be due to the theory that mutant P53 may directly 
activate the PCNA promoter. Mutant P53 and PCNA expression was also found to be highest 
in non-oat cell SCLC by Korkolopoulou et al (1993). These results were further supported by 
a study showing abnormal P53 protein accumulation in 45% of intermediate cell and 11% of 
oat cell SCLC. A distinct inverse relationship between P53 immunocytochemistry and 
apoptosis in SCLC was also noted (Eerda et al, 1997). Data concerning the reliability of 
immunocytochemistry in detection of P53 mutations remains conflicting. In 1994 Gazzeri, 
Brambilla, Caron de Fromental, Gouyer, Moro, Perron, Berger and Brambilla demonstrated a 
strong correlation between P53 gene mutations and abnormal P53 protein expression as 
detected by immunocytochemistry. Wiethege, Voss and Miller (1995) also recommended the 
use of immunocytochemistry for detecting P53 mutations. However, Casson, McCuaig, 
Craig, Ayed, Inculet, Kerkvliet and O'Malley (1994) found immunocytochemistry to 
correlate poorly with genetic analysis when examining P53 mutations. One of the major 
problems in this argument is that very rarely has the immunocytochemical threshold been set 
using an objective basis (Dowell and Hall, 1995). A cautionary note on the excessive use of 
antigen retrieval techniques in P53 immunocytochemistry was given by Baas et al (1996). 
Statistical analysis of the results of this study showed P53 to be able to predict patient 
survival in combination with some other markers, although not being statistically significant 
itself it is related to the other markers to such an extent that they lose significance if P53 is 
removed from the combination. P53 was also found to be expressed at a higher level in 
intermediate cell type rather than oat cell type SCLC. A reciprocal expression of BCL-2 and 
P53 expression was not noted in this study. 
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5.3.2 Retinoblastoma 
The rb gene was the first tumour suppressor gene isolated (Knudson, 1971). It has now been 
mapped to chromosome 13g14 and codes for a 105 kD nuclear phosphoprotein. The 
phosphorylation state of the RB protein varies throughout the cell cycle, with a maximum in 
S phase and a reduced phosphorylation after M phase. This indicates that the protein acts in a 
cell cycle specific way to regulate cell proliferation, which function may be carried out by the 
underphosphorylated form, while the phosphorylated form may participate in the control of 
growth inhibitory activities. RB protein can also protect cells from p53-dependent apoptosis 
(Kouzarides, 1995). 
A study on SCLC tumours and cell lines using a rb cDNA probe showed that abnormalities in 
structure and expression of the rb gene are common in SCLC and atypical pulmonary 
carcinoids, but rare in other lung cancer cell types (Harbour et al, 1988). In fact, Hensel et al 
(1990) reported inactivation of rb to be a frequent, if not universal, event in SCLC. In SCLC 
mutations of the rb gene are almost always present, but are seen in only about 20% of 
NSCLC. The protein may be expressed in SCLC but it usually lacks phosphorylation and is 
of an abnormal size (Gazdar, 1992). Abnormalities of both rb alleles, abnormal gene 
transcription products or absence of RB protein is almost always seen in SCLC, but in only 
10-20% of NSCLC (Kern and Filderman, 1993). A large study by Reissmann et al in 1993 
found rb gene inactivation in approximately one third of the NSCLC examined. They also 
reported immunocytochemistry to be very sensitive in detecting RB inactivation. Further 
evidence was provided in a study that found 88% of SCLC to be negative for the RB protein 
and only 23% of the NSCLC examined to be positive for abnormal RB protein expression, 
indicating that abnormalities of RB protein may be a minor event in NSCLC (Higashiyama et 
al, 1994). 
The RB protein was not found to be of any statistical significance or to have any associations 
with any other markers used in this study. However, the results do confirm the previously 
published data by demonstrating a low incidence of RB protein expression in SCLC (5%). 
This is also the first time a quantitative study has been performed on this antigen, and it 
showed that even when the protein is expressed it is not at particularly high levels. RB was 
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never likely to achieve any statistical significance as of the 31 results used for statistical 
analysis there were only two RB positive results. 
5.3.3 NM23 
nm23 is a putative metastasis suppressor gene which was isolated on the basis of it's reduced 
expression in murine melanoma cell lines of high metastatic potential (Steeg et al, 1988). 
Two human nm23 genes - nm23-H1 and nm23-H2 - which are 88% homologous have been 
described (Stahl et al, 1991). The genes are on chromosome 17g22, l8kb apart, and encode 
for the two polypeptide subunits of a nucleoside diphosphate kinase (NDPK) 
(Chandrasekharappa, Gross, King and Collins, 1993; Backer et al, 1993). nm23 has been 
shown at both the level of the protein and mRNA to have a higher expression in breast tissues 
of low metastatic potential than in corresponding high metastatic variants. However, in other 
tumours e. g. lung cancers no association between nm23 expression and metastasis has been 
reported. 
Low tumour nm23 rnRNA content has been found to correlate with significant disease-free 
and overall survival in breast cancer patients (Hennessey et al, 1991). NM23 protein 
expression has been reported in colon adenocarcinomas (Royds, Cross, Silcocks, Scholefield, 
Ross and Stephenson, 1994). 
Reduced expression of the nm23 gene is closely associated with distant metastases in human 
hepatocellular carcinomas (Nakayama et al, 1992), and with the early appearance of 
metastases after diagnosis of malignant melanoma (Florenes et a1,1992). In contrast, an 
increased NM23 protein level in neuroblastoma has been reported to be associated with the 
aggressive stages of the disease. A study in 1993 (Backer et al) showed NM23 expression to 
increase with the grade of malignancy in all NSCLC, except adenocarcinomas. A study by 
Higashiyama et al in 1992 looked at NM23 expression, using an antibody to NDPK, in 
pulmonary adenocarcinomas. They found no relationship between NDPK expression and 
grade of malignancy in this type of lung tumour. 
The results of this study implicated NM23 to be by far the most significant of all the markers 
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studied. Upon multiple regression analysis the best single predictor of survival was NM23, 
and it was also included in the best combination of markers. NM23 protein was found to be 
expressed at a much higher level in intermediate type than in the positive cases of oat cell 
type SCLC. This appears to be possibly indicative of the role of NM23 protein expression as 
a possible positive prognostic indicator in SCLC, as it is expressed at higher levels in the less 
aggressive intermediate cell type in comparison with the few cases in which it is expressed in 
the oat ell type SCLC. As no published work on NM23 protein expression, quantitative or 
subjective, has been found a comparison with other authors work is not possible at this time, 
but it does provide an interesting area for possible future studies. 
5.4 OVERALL CONCLUSIONS 
The original aim of this study was to develop a method for isolating single whole SCLC cells 
from formalin-fixed, paraffin-embedded tissue and immunostaining the cell monolayer 
produced. However, although it was technically possible to produce a single cell monolayer 
of tumour cells from archival material they were unable to be reliably immunostained despite 
various attempts to improve the cells permeability. The study then reverted to a serial 
histological section approach using a panel of 10 immunocytochemical markers and 
quantitating a proportion of the cases objectively using digital image analysis. As the results 
were analysed they were found to be possibly relevant to predicting survival by means of a 
possible panel of immunocytochemical markers. The markers studied showed differences in 
relevance for survival prediction, indeed some of the markers selected (such as NM23) had 
not previously been studied in SCLC and so these results are preliminary as there are no other 
studies for comparison. 
This study itself is novel in several ways, the major way being the extensive quantitative 
digital image analysis carried out. The value of objective numerical techniques cannot be 
stressed enough, as they remove observer bias and allow for direct comparison of results 
between different laboratories, even using different techniques due to the use of both internal 
and external controls. Also, the number of cases included within the study lend more validity 
to the statistical data derived, especially when the objective data can be used to compare the 
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general trends observed in the much larger series of subjective data obtained. 
All the markers used in this study were correlated to some degree, the majority being 
positively correlated. This reflects the essentially heterogeneous nature of lung cancers and 
the fact that there is no "magic marker", thereby leading to the conclusion that a panel of 
markers is to be the only likely way of getting useful information from tumours. Which is 
logical when the range of mutations produced by tobacco smoke is considered, because 
cigarette smoke is known to be the major cause of lung cancer generally and is linked to 
SCLC particularly, and it produces a large range of mutations therefore a large panel of 
markers would be needed to detect these changes either to reflect diagnosis or survival 
prediction. Although NM23 was found to be the best single predictor of survival it was even 
better when placed in combination with four other markers - PCNA, P53, Mib 1 and C-MYC. 
Even after taking into account the clinical data this remained the most useful marker 
combination feasible from the range of markers used within this study. 
Also, for the vast majority of the markers used within this study it was the first time that a 
quantitative image analysis system had been used to assess the expression of the markers. 
Although the image analysis system is quoted as being objective there is still an element of 
subjectivity as the operator sets the threshold limits, and is inevitably responsible for selecting 
the field to be measured. There was a definite difference in expression between some 
markers in the histological subtypes, although only three of the markers from the selected 
panel showed this difference in staining intensity, and it was the only point where BCL-2 
stood out. One problem was the high numbers of MDM-2 positive cases included in the 
study which precluded any statistically significant results from this marker, but that is just an 
unfortunate result of using "blind" data (i. e. had no preconceived notions of what the results 
should or would be). The important thing to remember is that the oncogenic markers used 
within this study looked at protein products of genes, not the actual genes themselves. 
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5.5 FUTURE WORK 
The main purpose of any future work needs to be to duplicate the study already carried out on 
a different series of patients. The regression equation that was generated from this study to 
predict survival should then be applied to the data obtained from each patient to verify the use 
of the panel of markers suggested. Another avenue would be to carry out a similar study 
using different markers, either immunocytochemical or biochemical, to study in more detail 
how information on oncoproteins, proliferation and apoptosis can improve the diagnosis and 
predict prognosis and survival times in SCLC. As well as using different markers, a range of 
techniques could be evaluated for the same reasons. A larger quantitative study would be 
useful in terms of improving the statistical value of the analysis of the results, and this may 
become more likely as computer technology is constantly improving and image analysis 
systems are upgraded, so the element of subjectivity inherent in these systems presently where 
the operator has to set the threshold limits could be eliminated. 
In terms of individual markers NM23 definitely requires further investigation in all types of 
lung cancer quantitatively. A more detailed study of the dynamics of the relationship of 
expression between P53, BCL-2 and CMYC as well as between P53 and MDM2 would also 
be of great value and much interest. Also further investigations on the differences of 
expression of markers such as P53, NM23, BCL-2 and Mibl within histological subtypes to 
provide more information that could lead to an improvement in prognostic assessment. An 
interesting study would be to look at lung cancers as a whole to see if there are any major 
discrepancies that form a cut-off point between different histological types and sub-types, as 
there are often mixed tumours reported. 
It would also be useful to attempt a prospective study of SCLC patients to see when markers 
become expressed and how they interact through the course of the disease. This would be 
possible as advances in histological and cytological techniques are producing less and less 
invasive methods for sampling tumours. A possible avenue available for exploration on 
prospective material is to study how or if the levels of selected markers for predicting survival 
alter if a patient stops smoking tobacco, both in terms of genes and gene products. The 
majority of work to be carried out at the Cause For Hope Lung Cancer Research Foundation, 
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Liverpool is to be based upon genetic research which could provide a useful comparison to 
the work on gene products carried out in this study. Indeed as areas such as in situ 
hybridisation continue to advance and easy to use kits are developed it should become as 
relatively quick and simple to detect genetic alterations directly as it is currently to detect 
protein products using immunocytochemical techniques. 
The main advantage of computerised numerical techniques becomes apparent on cytological 
samples such as bronchial brushings and washings and sputum samples, which is the type of 
material most often collected in prospective studies. These samples contain relatively few 
malignant cells and positive reactions may be easily missed subjectively, which is unlikely 
objectively. It would also be useful to have multi-centre trials carried out nationally and 
internationally on both prospective and a retrospective basis. These sort of studies would 
highlight regional and geographical differences in lung cancer incidence and survival 
generally, but most especially in the highly aggressive SCLC. Organisations such as the 
Cause For Hope Foundation with offices in other areas of the country, as well as having its 
headquarters in Merseyside which is quoted as the lung cancer capital of England, would be 
ideally suited to initiate this type of study at a national level. 
In summary the large series of cases studied in a unique study using a wide range of markers 
assessed in the most objective way possible have provided a great deal of useful data and 
proposed many more avenues of possible future research. As computer and medical 
technology continue to advance then more and more can be understood about the nature of 
the human body and how it becomes disrupted in conditions such as cancer. Each novel piece 
of work contributes to this understanding in some way, which will ultimately benefit the 
patients involved. It is hoped that this study will go some way towards providing a shift in 
the direction of research in the area of SCLC towards the computerised, standardised 
objective interpretation of results especially in large studies such as this. 
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APPENDIX I- Abbreviations 
SCLC - small cell lung cancer 
NSCLC - non-small cell lung cancer 
DNES - diffuse neuro-endocrine system 
ACTH - adrenocorticotrophic hormone 
ADH - anti-diuretic hormone 
PCNA - proliferating cell nuclear antigen 
DNA - deoxyribose nucleic acid 
RNA - ribose nucleic acid 
NOR - nucleolar organizer region 
AgNOR - silver staining nucleolar organizer region 
WHO - World Health Organization 
DMF - dimethylformadide 
PVP - polyvinylpyrollidine 
PEG - polyethylene glycol 
TBS - tris-buffered saline 
PBS - phosphate-buffered saline 
PVA - polvinyl acetate 
ABC/AP - avidin-biotin complex/ alkaline phosphatase 
BRAM - biotinylated rabbit anti-mouse antibody 
NRS - normal rabbit serum 
RLUHT - Royal Liverpool University Hospital Trust 
5-HT - 5-Hydroxytryptamine 
Rb - retinoblastoma 
H&E - haemalum and eosin stain 
HCl - hydrochloric acid 
Tris - Tris(hydroxymethyl)methylamine 
NaOH - sodium hydroxide 
BSA - bovine serum albumin 
cDNA - complementary DNA 
M phase - mitotic phase 
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S phase - synthetic phase 
G phase - gap phase 
TLI - thymidine labelling index 
BrdU - bromodeoxyuridine 
CDK - cyclin dependent kinase 
ICE - interleukin-lß-converting enzyme 
ISEL - in situ end labelling 
APES - 3-aminopropyltriethoxysilane 
RT - room temperature 
ABC/HRP - avidin biotin complex / horesradish peroxidase 
APAAP - alkaline phosphatase anti-alkaline phosphatase 
LVN - low viscosity nitrocellulose 
TCA - trichloroacetic acid 
Mdm-2 gene - mouse double minute 2 gene 
Bcl-2 gene -B cell leukaemia and lymphoma 2 gene 
mRNA - messenger RNA 
DAB - 3-3'diaminobenzidine 
nm23 gene - non-metastasizing gene 
nm23-H1 - nm23 homologue 1 
C. O. S. H. H - Control Of Substances Hazardous to Health 
OD - optical density 
DA - detected area 
CV - co-efficient of variation 
ANOVA - analysis of variance 
MANOVA - multiple analysis of variance 
SD - standard deviation 
SE - standard error 
RGB - red green blue 
HSI - hue saturation intensity 
Mibc - Mib 1 centre 
Mib e- Mib 1 edge 
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EGFR - epidermal growth factor receptor 
FISH - fluorescent in situ hybridisation 
RFLP - restriction fragment length polymorphism 
SSCP - single strand conformational polymorphism 
NDPK - nucleoside diphosphate kinase 
rRNA - ribosomal RNA 
kD - kiloDalton 
D. P. X. - dibutylthalate in xylene 
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APPENDIX 11 - Materials 
Supplied by Sigma chemical company : 
Naphthol AS-MX phosphate (cat-N4875) ; Fast red violet LB salt (cat-F-3381) ; Levamisole 
(cat-L9756) ; Naphthol AS-TR phosphate (cat-N6125) ; 5-bromo-4-chloro-3-indolyl 
phosphate, toluidine salt (cat-B8503) ; Tetranitro BT (cat-T4000) ; Fast blue RR salt (cat- 
F0500) ; 3-aminopropyltriethylsilane (APES)(cat-A3468) ; Collagenase IV (cat-C1538) ; 
Protease XXIV (cat-D8001) ; Polyvinylpyrrolidine (PVP) (cat-PVP40) ; Proteinase K (cat- 
P6556) ; 0.05% Trypsin-EDTA solution (cat-T3924) ; 3-3' diaminobenzidine (cat-D800 1) ; 
Schiffs reagent (cat-395-2-016) ; Dimethylformamide (cat-28425) 
Supplied by BDH : 
New Fuchsin (cat-34184) ; Fast red B salt (cat-34119); Silver nitrate (cat- 10233 3J) ; Gelatine 
powder (cat-44045 4B) ; Tris(hydroxymethyl)methylamine (cat-27119) ; Sodium chloride 
(cat-30123) ; Trisodium citrate (cat-10242) ; Sodium nitrite (cat-30188) ; Paraformaldehyde 
(cat-29447); Hydrochloric acid (cat-28507) ; Sodium hydroxide (cat-30617) ; Bovine serum 
albumin, fraction V (cat-44155) ; Polyethylene glycol 20 000 (cat-29864) ; Hydrogen 
peroxide solution, 30% (cat-10128) ; Cloroauric acid (gold chloride) (cat-19049) ; Sucrose 
(cat-30299) ; Polyethylene glycol 1500 (cat-29575 4U) ; Iron (III) chloride (cat-10110) ; 
Oxalic acid (cat-29423) ; Chloral hydrate (cat-27668) ; Eosin Y (cat-34027) ; Light green 
(cat-34043) ; Aluminium potassium sulphate (potassium alum) (cat-10009) ; Glycerol (cat- 
284546F) ; Sodium sulphite (cat-30223) ; Formic acid (cat-28429) ; DPX mountant (cat- 
36029 4H) ; Lithium carbonate (cat-29065) ; Sodium iodate (cat-30171) ; Glacial acetic acid 
(cat-27013) ; Trichloroacetic acid (cat-30489) ; Low viscosity nitrocellulose wool (cat- 
36013) ; Triton X-100 (cat-30632) ; Diethyl ether (cat-28132) ; Industrial methylated spirits 
(absolute alcohol) (cat-30244) ; Chromium (III) potassium sulphate (chrome alum) (cat- 
27758) ; Calcium chloride (cat-10069) ; Sodium thiosulphate (cat-30236) ; Acetone (cat- 
27023) ; Methanol (cat-26129) ; Disodium hydrogen phosphate (cat - 10249) ; Sodium 
dihydrogen phosphate ( cat-10245) ; Calcium nitrate (cat-27607) 
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Supplied by DAKO : 
Rabbit anti-mouse biotinylated immunoglobulins (cat-E354) ; Streptavidin-biotin 
complex/alkaline phosphatase (cat-K391); Bcl-2 oncoprotein, mouse anti-human (cat-M887) 
; Proliferating cell nuclear antigen monoclonal antibody PC 10 (cat-M879) ; c-erbB-2 
oncoprotein polyclonal, rabbit anti-human (A485) ; Swine anti-rabbit biotinylated 
immunoglobulins (E353) ; Strept ABC/AP kit (cat-K377) ; APAAP mouse monoclonal (cat- 
D65 1) ; Rabbit anti-mouse immunoglobulins, absorbed with rat immunoglobulin (cat-2456) ; 
Monoclonal mouse anti-human p53 protein (cat-M7001) ; Dako pen for 
immunocytochemistry (cat-S2002) 
Supplied by Novocastra Laboratories : 
C-myc oncoprotein monoclonal antibody (cat-NCL-CMYC) ; Mdm-2 monoclonal antibody 
(NCL-MDM2) ; Nm23 protein monoclonal antibody (cat-NCL-NM23) ; Retinoblastoma gene 
protein, mouse monoclonal (cat-NCL-RB) ; Retinoblastoma gene protein, mouse monoclonal 
(cat-NCL-RB 1) ; C-erbB-2 oncoprotein, mouse monoclonal (cat-NCL-CB 11) 
Other Reagents : 
Aquaperm mountant (Immunon cat-484975) ; Mib-1 monoclonal antibody (Immunotech cat- 
0505) ; Polycarbonate membranes (25mm, 12µm pore size) (CoStar UK cat-I 10616) ; 
Polyvinyl acetate (PVA) (Aldrich cat-18949.9) ; Glass beads 1.01-1.27 mm diameter (ORME 
cat-G50-1 00) ; Normal swine serum (SeraLab cat-S-0005) ; Normal rabbit serum (SeraLab 
cat-S-0009) ; Biotinylated anti-mouse IgG (Vector cat-BA-9200) ; Retinoblastoma protein, 
monoclonal (Biogenex cat-MU-290-UC) ; Apoptag in situ hybridisation kit (Oncor cat- 
S 1700-kit) ; Optiprep (Nycomed cat-1030061) ; Citric acid (Hopkin and Williams cat-3224) ; 
Potassium hexacyanoferrate (Hopkin and Williams cat-698000) ; Haematoxylin (Raymond A 
Lamb cat-75290) ; Trypsin (Difco cat-0152-13-1) ; Nylon gauze, 100µm (Lockertex) 
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APPENDIX III - Preparation of Solutions 
0.2M TRIS BUFFER 
- Dissolve 24.2g of tris in 500m1 of distilled water 
- Add 70m1 1M hydrochloric acid 
- Mix well and make up to 11 with distilled water 
- Check pH is as desired 
40% SODIUM HYDROXIDE SOLUTION 
- Take 200g of sodium hydroxide 
- Add slowly to 300ml of distilled water, with stirring 
- Make up to 500m1 when cool (CAUTION! - Exothermic reaction) 
40% FORMALDEHYDE SOLUTION (From Paraformaldehyde) 
- Take 80g of paraformaldehyde 
- Add slowly to 200m1 of distilled water at 65 °C 
- Use constant stirring to dissolve (hotplate/stirrer) 
- Mix well for 1 minute 
- Add Iml of 40% sodium hydroxide solution 
- Mix for 5 min, with constant stirring 
- The solution should become clear and be of pH 9.3 
*This must all be carried out at 65°C, in a fume cupboard wearing gloves and goggles* 
- Seal the flask and cool to room temperature 
- Check pH is 7.2-7.4 
- Store at 4°C 
- DILUTE 1: 10 WITH DISTILLED WATER FOR USE 
CONCENTRATED 0.05M TBS pH7.6 
- Take 60.55g of Tris and add 85.2g of sodium chloride 
- Add 500m1 of distilled water and mix until dissolved 
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- Add approximately 185m1 of 2M hydrochloric acid to get pH7.6 
- Take final volume up to I litre with distilled water 
- Dilute 1: 10 with distilled water for use 
0.01M CITRATE BUFFER pH6.0 
SOLUTION A-0.1M citric acid (21.01g in 1 litre of water) 
SOLUTION B-0.1M sodium citrate (29.4g in 1 litre of water) 
- Take 9m1 of solution A and 41m1 of solution B 
- Make up to 500ml with distilled water and adjust pH to 6.0 
GADSDON'S HAEMALUM 
- Mix well together - 5.5g haemalum powder 
-100ml absolute ethanol 
- 20m1 glacial acetic acid 
- 600m1 filtered saturated aqueous potassium alum 
- Dissolve O. Sg of sodium iodate in l Oml of distilled water and add to above mixture 
- Mix well and leave for 1 hour 
- Add 300ml of glycerol and filter before use 
SCHOFIELD'S EOSIN 
- Prepare 1% eosin Y in o. 1% aqueous calcium nitrate 
- Filter before use 
CONCENTRATED PBS (0.5M pH7.2) 
- Prepare 0.5M disodium hydrogen phosphate 
- Add conc sodium dihydrogen phosphate to get pH 7.2 
- Add 9% sodium chloride 
- Dilute 1: 10 with distilled water for use to give 0.05M pH7.2,0.9% sodium chloride 
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PVA MOUNTANT 
- Dissolve 5g of PVA (polyvinyl acetate) in 20m1 of 80% ethanol 
- Leave for 24 hours to dissolve before use 
MAYERS HAEMALUM 
-Take 1 litre of distilled water 
- Add lg haematoxylin, 0.2g sodium iodate and 50g potassium or ammonium alum 
- Dissolve by warming and stirring or leave at room temperature overnight 
- Add 50g chloral hydrate and lg citric acid and boil for 5 min 
- Cool and filter (can use immediately) 
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APPENDIX IV - OBJECTIVE DATA 
CASE PCNA Mib e Mib c Cmyc Mdm2 cerbB2p Bcl-2 nm23 p53 cerbB2m 
4684/94 3.58 0.0 4.54 0.89 1.12 0.0 0.47 0.84 4.11 0.0 
5175/92 3.85 0.0 4.18 0.0 1.91 0.0 0.0 0.0 0.0 0.0 
15230/92 3.88 3.7 0.0 0.0 2.54 0.0 0.0 0.0 2.54 0.81 
8156/92 3.89 0.0 3.08 0.0 1.73 0.0 0.69 0.0 0.0 0.0 
9351/91 3.96 2.72 0.0 0.0 2.44 0.0 0.0 0.0 0.0 0.0 
5133/95 4.21 8.21 6.9 0.51 1.56 0.0 1.18 1.87 1.76 0.57 
5361/94 4.25 0.0 6.36 0.0 1.27 0.0 1.4 1.33 4.77 0.0 
6958/95 4.27 0.0 4.07 0.45 1.57 0.0 1.82 0.7 2.25 0.0 
1826/95 4.31 0.0 3.33 0.0 3.12 0.0 0.0 0.0 3.23 0.0 
13613/92 4.34 0.0 4.81 0.67 0.075 0.0 0.0 1.19 3.86 0.0 
2896/91 4.39 0.0 0.0 1.3 1.74 0.0 0.0 1.03 0.0 0.0 
4024/89 4.39 0.0 0.0 0.82 1.87 0.0 0.0 0.77 0.0 0.0 
12454/91 4.51 3.25 0.0 0.77 1.76 0.0 0.0 1.67 0.0 0.0 
6583/92 4.52 0.0 3.8 0.78 1.13 0.71 1.04 1.8 3.41 0.43 
11241/92 4.57 0.0 0.0 1.39 1.64 0.0 0.0 2.17 2.7 0.0 
841/95 4.59 0.0 3.92 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
6114/91 4.79 0.0 0.0 0.0 1.47 0.0 0.0 0.88 0.0 0.0 
6405/92 5.29 5.13 4.45 0.56 0.57 0.57 0.71 0.33 3.21 0.0 
10669/93 5.64 4.24 0.0 0.45 1.47 0.31 0.0 0.83 0.0 0.62 
4920/89 7.7 0.0 3.53 0.0 1.94 0.0 0.0 0.0 0.0 0.0 
9075/90 0.0 0.0 3.77 0.0 1.82 0.0 0.0 0.0 0.0 0.0 
6670/94 0.0 0.0 4.21 0.47 1.02 0.0 0.72 1.57 4.34 0.0 
428/93 0.0 0.0 0.0 1.1 0.0 0.0 0.88 0.0 0.0 0.0 
5589/89 0.0 0.0 0.0 0.0 2.72 0.0 1.21 0.0 0.0 0.0 
10084/90 0.0 0.0 0.0 0.43 1.72 0.0 0.0 0.99 0.0 0.0 
8074/92 0.0 0.0 0.0 0.0 2.26 0.0 0.0 1.11 0.0 0.0 
84/89 0.0 0.0 0.0 0.99 1.56 0.0 0.0 0.0 0.0 0.0 
2698/93 0.0 0.0 0.0 0.0 2.04 0.0 0.0 0.0 0.0 0.0 
11928/90 0.0 0.0 0.0 0.0 1.97 0.0 0.0 0.0 0.0 0.0 
15242/90 0.0 0.0 0.0 0.0 1.93 0.0 0.0 0.0 0.0 0.0 




Rb PLOIDY HIST SEX AGE CH RA SU SURV Logo 
SURV 
FITS 
4684/94 0.0 2 0 2 67 1 0 1 7 0.845 0.881 
5175/92 0.0 
, 
2 0 2 69 1 0 0 1 0.00 0.605 
15230/92 0.0 2 0 1 69 1 0 0 51+ 1.708 1.619 
8156/92 0.0 1 0 2 72 1 0 0 3 0.477 0.507 
9351/91 2.51 2 0 1 77 0 1 0 7 0.845 0.676 
5133/95 3.12 1 1 1 45 1 1 1 4 0.602 0.738 
5361/94 0.0 2 1 1 67 1 1 1 28+ 1.447 1.396 
6958/95 0.0 2 1 1 61 1 1 1 16 1.204 0.977 
1826/95 0.0 1 0 2 74 0 1 0 3 0.477 0.549 
13613/92 0.0 1 1 1 73 1 1 1 7+ 0.845 1.054 
2896/91 0.0 2 0 2 44 1 1 0 56 1.748 0.939 
4024/89 0.0 2 0 1 65 1 0 1 3 0.477 1.071 
12454/91 0.0 2 1 1 68 1 1 1 46 1.663 1.415 
6583/92 0.0 2 0 2 67 0 1 0 5 0.699 0.633 
11241/92 0.0 2 1 2 56 1 0 1 28+ 1.447 1.645 
841/95 0.0 2 0 2 69 1 0 0 11 1.771 1.329 
6114/91 0.0 1 0 2 71 1 0 1 59+ 0.477 0.539 
6405/92 0.0 2 0 2 69 0 0 0 3 1.568 1.605 
10669/93 0.0 2 0 1 54 1 1 1 37+ 0.954 1.086 
4920/89 0.0 2 0 2 44 1 1 0 9 1.041 0.244 
9075/90 0.0 2 0 1 69 1 1 0 11 1.279 1.060 
6670/94 0.0 2 1 1 57 1 0 1 19 0.00 0.409 
428/93 0.0 2 0 2 51 0 0 0 1 0.301 0.533 
5589/89 0.0 2 0 2 69 1 0 0 2+ 1.041 0.889 
10084/90 0.0 2 0 1 57 1 1 0 11 0.301 1.054 
8074/92 0.0 2 0 1 52 1 0 0 2 0.00 0.00 
84/89 0.0 1 0 1 66 1 0 0 1 0.903 0.614 
2698/93 0.0 2 0 2 66 1 1 0 8 0.00 0.622 
11928/90 0.0 2 0 2 75 1 0 0 1 0.778 0.628 
15242/90 0.0 2 0 2. 63 1 1 0 6 1.041 0.653 
15394/88 0.0 2 0 1 65 1 1 0 11 1.041 0.967 
Table 5: Full objective data on 31 cases used 
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KEY FOR TABLE 5 
HIST = Histological subtype -0= oat cell, 1= non-oat cell 
CH = chemotherapy -0= not treated, 1= treated 
RA = radiotherapy -0= not treated, 1= treated 
SU = surgery -0= not treated, 1= treated 
SURV = survival -+ indicates still alive when records ceased on patient 
SEX -1= male, 2= female 
FITS = predicted survival 
CASE PCNA Mib e Mib c C-myc Mdm2 C-erbB2 p 
12859/94 3.78 0.0 4.61 0.82 1.27 0.44 
9132/90 5.25 3.43 3.42 0.615 1.69 . 052 
12828/88 0.0 0.0 0.0 0.0 0.0 0.0 
4580/92 4.64 0.0 4.4 0.7 1.97 0.0 
15131/88 4.08 0.0 0.0 0.0 1.5 0.0 
10151/94 3.65 5.35 4.64 0.61 0.92 0.0 
9628/95 0.0 0.0 0.0 0.0 1.19 0.0 
13861/92 0.0 2.38 0.0 0.0 1.75 0.0 
4155/92 4.6 3.3 3.79 0.6 1.43 0.29 
3939/89 0.0 0.0 0.0 0.0 2.64 0.0 
248/89 0.0 0.0 2.67 0.0 1.34 0.0 
310C/89 0.0 0.0 0.0 0.99 1.23 0.0 
310D/89 0.0 0.0 4.23 0.0 0.0 0.0 
2953/88 0.0 0.0 3.42 0.106 1.77 0.0 
3007/90 4.05 2.56 2.64 0.0 1.08 0.0 
15041/89 4.54 0.0 3.74 1.16 2.26 0.0 
7761/89 5.9 2.33 3.3 0.86 1.92 0.0 
15470/92 4.71 0.0 0.0 0.67 1.41 0.587 
9136/89 4.9 0.0 3.85 0.0 2.02 0.0 
1759/87 5.19 0.0 4.72 1.33 2.00 0.065 
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CASE Bcl-2 nm23 cerbB2 m p53 Rb PLOIDY 
12859/94 0.0 0.0 0.0 0.0 3.08 2 
9132/90 0.0 0.99 0.0 0.0 0.0 2 
12828/88 0.0 0.0 0.0 0.0 0.0 2 
4580/92 0.0 0.0 1.14 0.0 0.0 2 
15131/88 0.0 0.96 0.0 0.0 0.0 1 
10151/94 0.0 0.96 0.0 0.0 0.0 1 
9628/95 0.0 0.0 0.0 3.64 0.0 1 
13861/92 0.0 0.0 0.72 1.95 0.0 1 
4155/92 0.0 1.47 0.65 0.0 0.0 2 
3939/89 0.0 0.0 0.0 0.0 0.0 2 
248/89 0.0 0.0 0.0 0.0 0.0 1 
310C/89 0.72 0.0 0.0 0.0 0.0 1 
310D/89 0.45 0.0 0.0 0.0 0.0 2 
2953/88 1.06 0.0 0.0 0.0 0.0 2 
3007/90 1.36 1.17 0.0 0.0 0.0 2 
15041/89 0.0 0.0 0.0 0.0 0.0 1 
7761/89 0.0 1.21 0.0 3.52 0.0 3 
15470/92 0.5 1.72 0.91 3.46 0.0 2 
9136/89 0.0 0.91 0.0 0.0 0.0 1 
1759/87 0.0 0.62 0.0 2.99 0.0 2 
Table 6: Objective data on further 20 cases where clinical data unavailable 
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APPENDIX V- FULL SUBJECTIVE DATA 
CASE Mibl PCNA p53 Rb Bcl-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
3369/89 - ++nr -- + ++ +++ + 
1759/87 +++n +++nr +++n - - ++ +++ +++ - + 
9132/90 ++r +++nr -- - + ++ ++ _ ++ 
10669/93 +n +++nr -- - ++ +++ ++ - + 
733/88 - ++n -- - - ++ ++ - - 
15470/92 - +++nr +++nr - + + +++ +++ +++ ++ 
7761/89 +n +++nr +++nr - - ++ ++ ++ 
12454/91 ++r +++nr -- + ++ ++ ++ - - 
6405/92 +++nr +++nr ++n - + + + ++ - + 
11449/94 +++r +++r +++nr - - + ++ ++ + + 
2457/87 +n +r ++r - - + ++ + - - 
14632/94 ++r +nr ++nr - - - ++ ++ + + 
12859/94 ++r ++n - ++nr - - +++ +++ - ++ 
4155/92 ++nr +++nr -- - ++ +++ ++ + + 
6958/95 +++nr +++nr ++n - +++ + +++ ++ 
10226/88 +r - +++ + ++ ++' + - 
4623/88 -- +++ + ++ ++ + - 
11974/89 +n +r ++r + ++ ++ + 
10123/88 
% 
+r + ++ + + 
10146/87 + + + 
10297/91 ++r ++ + - 
3569/87 +n +n +nr - +++ - +++ + + - 
3691/87 - +nr -- ++ - +++ ++ ++ + 
6583/92 +++r +++nr +++nr - ++ +++ ++ ++ ++ + 
15473/87 - - ++r - ++ _ ++ - + - 
5076/88 '+nr - +nr - - +++ - - - - 
14186/90 - +nr -- + ++ - ++ - - 
13501/87 +n +nr +n - ++ - - + + - 
1392/87 - - -- - - +++ ++ + - 
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CASE Mibl PCNA p53 Rb BcI-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
6923/87 +n ++r +n - ++ - ++ + + - 
10048/88 +n - ++n - - - ++ - - - 
15310/88 +nr - ++r - + - + + + - 
9652/88 +n - - - + - ++ + 
482/87 +n - +++r - +++ - ++ + - 
8581/87 - +nr - - - - + + - - 
11177/88 +n +nr ++r - - - ++ ++ - - 
15159/87 - - +nr - - + - - - 
1491/87 - - ++r + + - - 
13974/87 - - - - - - + - - - 
2186/95 - ++nr - - - + +++ - - 
558/93I ++r - - ++nr - - +++ + - - 
558/93 E ++r - - - - - ++ ++ - - 
3007/90 ++n +++n - - +++ +++ +++ + 
546/90 A ++r - - +nr - - ++ ++ - - 
546/90 B +++nr - - - - - ++ ++ - - 
788/87 - - - - - - ++ - - - 
6399/87 +n +r ++nr - ++ + +++ + - - 
441/90 ++r ++nr +nr ++nr - + +++ + - - 
248/89 +n - - - - - ++ - - - 
4684/94 +++nr +r +++nr - ++ +++ ++ + - - 
13613/92 +++nr ++nr +++nr - - ++ + ++ - - 
10151/94 +++nr +r - - - ++ ++ ++ - - 
428/93 - - - - +++ - - + - - 
21/95 +++r +r - - - ++ ++ - - 
5133/95 +++nr +++nr ++n ++nr ++ +++ +++ + + - 
319/89 +n - - +nr - ++ + - - 
5361/94 +++nr ++nr +++nr - +++ +++ + - - - 
84/89 - - - - - - +++ ++ - - 
6670/94 +++nr - +++nr - ++ +++ +++ + - - 
310/89 C - - - - + - + + - - 
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CASE Mibl PCNA p53 Rb Bcl-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
310/89 D +n - - - + 
6449/94 +++nr ++nr +++nr ++ _ ++ ++ 
6462/87 +nr - +nr - - ++ + 
4142/88 +n +n - - ++ - - + _ 
13977/87 - - - - - - ++ - - 
2953/88 +n - - - + - +++ + _ 
6224/91 ++r 
10106/90 - - - - - - + - - - 
2768/90 +n - ++ - ++ - - - 
1018/91 ++r - - - - - +++ - _ _ 
5194/90 - - - - - - ++ 
2492/89 +nr - - - - - ++ - - - 
2698/93 - - - - - - + - - 
13861/92 +nr - +nr - - - +++ - + - 
11225/90 - - - - - - - - - - 
13396/94 +nr +++nr - - - - ++ - - - 
13152/91 - - - - - - ++ + + + 
841/95 ++nr +r - - - - - - - - 
780/92 - - - - - - ++ + 
9075/90 ++nr - - - - - ++ - - - 
14003/90 +nr ++ - ++ - 
6352/91 - - - - - - ++ - - - 
7920/95 +++nr - - _ _ +++ - - 
7037/95 +++nr - - _ - - + - - - 
5544193 ++r - - - _ - +++ + ++ + 
15216/88 ++r - - - - - ++ - - - 
11928/90 - +nr _ - _ - +++ - - - 
731/90 - - - - - ++ - - - 
9351/91 ++r ++m _ +n ++ 
1826/95 ++nr +++ s +n - - - +++ - - - 
16786/92 +nr ++r +nr -F+ - - - 
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CASE Mibl PCNA p53 Rb Bcl-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
3558/94 +++r ++nr - - - - ++ 
8156/92 ++r +++r - - ++ - ++ 
4920/89 ++r ++r - - - - ++ 
5175/92 +++nr ++nr - - - - + - - 
8086/91 ++r +++nr +r - ++ 
3276/91 +nr ++r - - - - ++ - + - 
4580/92 +++nr ++nr - - - - ++ + + 
307/91 +nr - - - - ++ - + _ 
14818/93 - - - - - - + - - 
2071/89 - - - - - - ++ - - - 
14424/94 - - - - - - + - - - 
10149/93 - +nr - - - - ++ - - - 
6786/91 +nr - - - - - ++ 
9628/95 - - +r - - - ++ - 
15242/90 - - - - - - ++ - - 
4970/92 - - - - - - - - - - 
13691/92 - +nr - - + + ++ - - - 
1230/92 - - - - - ++ 
1976/92 +n - - - ++ 
7883/90 - - - - - - ++ + - - 
12393/92 - ++r - - - + - - 
8890/90 - - - - - ++ + - _ 
10447/89 - - - - - ++ - ++ 
5595/90 - - - - - + - - - 
17147/92 - - - - - - ++ - - - 
3191/92 - - - - + +++ + 
14494/89 - - - - - + ++ - - - 
6195/92 - - - - - - ++ - - 
6652/90 ++ - - - 
5896/91 - - - - - - ++ - - - 
11419/93 - - - - ++ - - - 
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CASE Mibl PCNA p53 Rb BcI-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
706/89 ++r - - - - - ++ - - - 
2699/89 - - - - - ++ - - - 
4922/89 - - - - - - ++ - - - 
12589/92 - ++r - - + - +++ - 
3168/95 - ++nr - - + + ++ + - - 
16220/90 - - - - - + ++ - - - 
12828/88 - - - - - - - - - 
7304/91 - +n - - - ++ +++ ++ ++ . 
10084/90 - - - - + ++ + - - 
14815/90 - - - - - + + + - 
3369195 +nr +nr - - - - ++ - - - 
2410/91 - - - - - - ++ - 
13749/88 - - - - - - ++ + - 
3939/89 - - - - - - + - - - 
11221/91 ++r ++nr - - - - +++ + - 
10268/91 - +++nr + - +++ 
712/89 +n ++r - - - - ++ - - - 
7124/92 +n ++nr - - - + ++ - - 
15394/88 - - - - - - ++ - - 
15070/94 - ++nr - - - - + - - 
9684/91 - ++nr - - + - + + - - 
7132/90 - +nr - - - - + - - - 
5410/92 +n +++nr - - - - ++ - - - 
10088/90 - +nr - - - ++ + - - 
3583/95 ++nr - - - - + - - - 
12259/90 - - - - - - + - - 
5073/90 - - - - - - + - - 
5589/89 - - - - + ++ - - - 
13084/90 - - - - - - + - - - 
8074/92 - - +n - + +++ - - - 
2896/91 - +n - - - + +++ ++ - 
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CASE Mibl PCNA p53 Rb Bcl-2 nm23 Mdm2 Cmyc cerbB2m cerbB2p 
816/91 - +nr - - - - ++ - - - 
15230/92 ++r +nr +r - - - +++ + - 
12825/89 - - - - - - + + - 
6827/93 +n ++r - +r - - +++ - - 
12260/88 - - - - - - ++ 
16088/94 - +nr - - - - ++ - - 
15131/88 - ++nr - - - + +++ 
1909/89 - +n - - - - ++ + ++ - 
4024/89 - ++nr +nr - + +++ + . 
9136/89 +n +++nr - - - ++ +++ - - - 
15041/89 +n +++nr - - - - +++ + - - 
1505/90 - - - - + - ++ - - - 
3887/90 - ++nr - - ++ + +++ + . 
6114/91 - ++nr - - - + ++ - - - 
7684/91 +n ++r - - - + ++ - - - 
8111/91 - ++nr - - - +++ + - . 
15087/91 - +++nr ++nr - - - +++ - - - 
497/92 - ++r - - - - + - - - 
11241/92 - ++nr +n - - +++ +++ + - . 
Table 7: Full subjective results assessed semi-quantitatively 
KEY FOR SUBJECTIVE RESULTS TABLE 
-= negative 
+= weak positive 
++ = moderate positive 
+++ = strong positive 
n= result based on number of positive cells 
r= result based on strength of reaction 
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APPENDIX VI - DETAILS OF STATISTICAL ANALYSIS 
One-Way Analysis of Variance 
Analysis of Variance on P53 
Source DF SS MS Fp 
hist 1 24.42 24.42 11.62 0.002 
Error 29 60.96 2.10 
Total 30 85.38 
Individual 95% CIs For Mean 
Based on Pooled StDev 
Level N Mean - StDev ----------+---------+---------+------ 
0 24 0.687 1.389 (---- *---- ) 
172.810 1.664 (-------- * ---------) 
----------+---------+---------+------ 
Pooled StDev = 1.450 1.2 2.4 3.6 
Analysis of Variance on NM23 
Source DF SS MS Fp 
bist 1 8.066 8.066 41.69 0.000 
Error 29 5.611 0.193 
Total 30 13.678 
Individual 95% Cls For Mean 
Based on Pooled StDev 
Level N Mean StDev ---------+---------+---------+------- 
0 24 0.2821 0.4286 (---*--) 
171.5021 0.4807 (------*------) 
---------+---------+---------+------- 
Pooled StDev = 0.4399 0.50 1.00 1.50 
Analysis of Variance on BCL2 
Source DF SS MS Fp 
hist 1 2.106 2.106 9.65 0.004 
Error 29 6.329 0.218 
Total 30 8.435 
Individual 95% CIs For Mean 
Based on Pooled StDev 
Level N Mean StDev ----------+---------+---------+------ 
0 24 0.2087 0.3896 (-----*-----) 
170.8322 0.6877 (----------*---------) 
----------+---------+---------+------ 
Pooled StDev = 0.4672 0.35 0.70 1.05 
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Analysis of Variance on MIBc 
Source DF SS MS Fp 
hist "1 29.01 29.01 6.41 0.017 
Error 29 131.28 4.53 
Total 30 160.29 
Individual 95% CIs For Mean 
Based on Pooled StDev 
Level N Mean StDev -------+---------+---------+--------- 
0 24 1.441 1.923 (----- *----- 
173.755 2.777 (----------*----------) 
Pooled StDev = 2.128 1.5 3.0 4.5 
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Correlations (Pearson)(Subjective data) 
mib-1 pcna p53 rb bcl-2 nm23 mdm-2 c-myc 
pcna 0.364 
p53 0.402 0.284 
rb 0.243- % 0.129 0.002 
bcl-2 0.214 0.149 0.383 -0.030 
nm23 0.316 ' 0.388 0.413 0.044 0.293 
mdm-2 0.100 0.245 . 0.088 0.202 0.041 0.178 
c-myc '0.302 0.289 0.378 0.128 0.253 0.311 0.122 
cerbb2m 0.079 0.079 0.221 -0.030 0.158 0.070 0.147 0.344 
cerbb2p 0.197 0.291 0.209 0.131 -0.004 0.147 0.165 0.522 
cerbb2m 
cerbb2p 0.402 
Correlations; (Pearson)(Objective data) 
PCNA MIBe ' MIBc CMYC MDM2 CERBB2p BCL2 NM23 
MIBe 0.328 
MIBc 0.373 0.188 
CMYC ' 0.141 0.050 -0.087 
MDM2 -0.120 -0.000 -0.366 -0.406 
CERBB2p 0.284 0.284 0.182 0.188 -0.265 
BCL2 0.080 0.193 0.477 0.121 -0.200 0.222 
NM23 0.212 0.267 0.168 0.481 -0.185 -0.131 0.209 
CERBB2m 0.261 0.641 0.055 0.001 0.095 0.348 0.082 0.053 
P53 0.265 0.084 0.632 0.216 -0.263 0.283 0.415 0.375 
RB 0.134 0.649 0.214 -0.054 0.127 -0.081 0.153 0.188 
PLOIDY -0.141 -0.122 -0.227 0.014 0.012 0.152 0.035 -0.073 
CERBB2m P53 RB 
P53 0.157 
RB 0.296 -0.030 
PLOIDY -0.039 -0.091 -0.238 
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ýi `ý ýs 
Correlations (Pearson)(objective and clinical data) 
PCNA MIBe MIBc ' CMYC MDM2 CERBB2p BCL2 NM23 
MIBe 0.328 
MIBc 0.373' 0.188 
CMYC 0.141 0.050 -0.087 
MDM2 -0.120 -0.000 -0.366 -0.406 
CERBB2p 0.284 0.284 0.182 0.188 -0.265 
BCL2 0.080 0.193 0.477 0.121 -0.200 0.222 
NM23 0.212 0.267 0.168 0.481 -0.185 -0.131 0.209 
CERBB2m 0.261 0.641 0.055 0.001 0.095 0.348 0.082 0.053 
P53 0.265 0.084 0.632 0.216 -0.263 0.283 0.415 0.375 
RB 0.134 0.649 0.214 -0.054 0.127 -0.081 0.153 0.188 
PLOIDY -0.141 -0.122 -0.227 0.014 0.012 0.152 0.035 -0.073 
SEX 0.046 -0.324 -0.073 -0.048 -0.044 0.161 -0.116 -0.414 
AGE -0.068 -0.172 0.014 -0.396 0.113 0.056 -0.090 -0.406 
chemo -0.132 -0.155 -0.068 -0.115 0.093 -0.545 -0.149 0.325 
radio 0.096 0.202 0.156 0.019 0.109 0.117 0.156 0.177 
surg 0.495 0.174 0.314 0.292 -0.229 -0.123 0.267 0.712 
hist 0.190 0.209 0.425 0.288 -0.251 -0.168 0.500 0.768 
CERBB2m P53 RB PLOIDY SEX AGE chemo radio 
P53 0.157 
RB 0.296 -0.030 
PLOIDY ' -0.039 -0.091 -0.238 
SEX -0.279 -0.124 -0.288 0.048 
AGE -0.182 0.120 -0.125 -0.176 0.073 
chemo -0.017 -0.212 -0.202 0.007 -0.222 -0.195 
radio 0.163 0.115 0.288 -0.048 -0.349 -0.037 -0.131 
surg ' 0.079 0.390 0.089 -0.114 -0.343 -0.256 0.349 0.077 





Regression Analysis on nm23 
The regression equation is 
log surv = 0.665 + 0.369 NM23 
Predictor Coef Stdev t-ratio p 
Constant 0.6645 0.1153 5.76 0.000 
NM23 0.3693 0.1329 2.78 0.009 
s=0.4916 R-sq = 21.0% R-sq(adj) = 18.3% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 1 1.8651 1.8651 7.72 0.009 
Error 29 7.0096 0.2417 
Total 30 8.8747 
Unusual Observations 
Obs. NM23 log surv Fit Stdev. Fit Residual St. Resid 
3 0.00 1.7076 0.6645 0.1153 1.0431 2.18R 
15 2.17 1.4472 1.4660 0.2319 -0.0188 -0.04 X 
R denotes an obs. with a large st. resid. 
X denotes an obs. whose X value gives it large influence. 
Regression Analysis on PCNA and nm23 
The regression equation is 
log surv = 0.491 + 0.319 NM23 + 0.0688 PCNA 
Predictor Coef Stdev t-ratio p 
Constant 0.4907 0.1470 3.34 0.002 
NM23 0.3191 0.1310 2.44 0.022 
PCNA 0.06881' 0.03815 1.80 0.082 
s=0.4736 " R-sq = 29.2% R-sq(adj) = 24.2% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 2 2.5947 ' 1.2974 5.78 0.008 
Error 28 6.2799 0.2243 
Total 30 8.8747 
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SOURCE DF SEQSS 
NM23 1 1.8651 
PCNA 1'0.7297 
Unusual Observations 
Obs. NM23 log surv Fit Stdev. Fit Residual St. Resid 
3 0.00 1.7076 0.7574 0.1224 0.9502 2.08R 
R denotes anobs. with a large st. resid. 
Regression Analysis on PCNA, nm23 and Mibc 
The regression equation is 
log sure = 0.540 + 0.340 NM23 + 0.0919 PCNA - 0.0655 MIBc 
Predictor' Coef ' Stdev ' t-ratio p 
Constant 0.5401 0.1456 3.71 0.001 
NM23 0.3400 , 0.1277 2.66 0.013 
PCNA 0.09190 0.03949 2.33 0.028 
MIBc -0.06555 0.03929 -1.67 0.107 
s=0.4592 R-sq = 35.9% R-sq(adj) = 28.7% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 3 3.1817 1.0606 5.03 0.007 
Error 27 5.6930 0.2109 
Total 30 " 8.8747 
SOURCE DF SEQ SS 
NM23 1 1.8651 
PCNA 1 0.7297 
MIBc 1 0.5870 
Regression Analysis on PCNA, nm23, Mibc and cmyc 
The regression equation is 
log surv = 0.609 + 0.448 NM23 + 0.0994 PCNA - 0.0792 MIBc - 0.332 CMYC 
Predictor Coef Stdev t-ratio p 
Constant 0.6088 0.1488 4.09 0.000 
NM23 0.4479 0.1427 3.14 0.004 
PCNA 0.09936 0.03881 2.56 0.017 
MIBc -0.07923 0.03932 -2.02 0.054 
CMYC -0.3319 0.2145 -1.55 0.134 
s=0.4478' R-sq = 41.3% R-sq(adj) = 32.2% 
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Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 4 3.6618 0.9154 4.57 0.006 
Error 26 - 5.2129 0.2005 
Total 30 8.8747 
SOURCE r; DF .- 
SEQ SS 
NM23 1 1.8651 
PCNA 1 0.7297 
MIBc 1 0.5870 
CMYC 1 0.4801 
Unusual Observations 
Obs. NM23 log surv Fit Stdev. Fit Residual St. Resid 
25 1.11 0.3010 ' 1.1055 0.2049 -0.8045 -2.02R 
R denotes an obs. with a large st. resid. 
Regression Analysis on PCNA, nm23, Mibc, cmyc and p53 
The regression equation is 
log surv = 0.625 + 0.406 NM23 + 0.102 PCNA - 0.120 MIBc - 0.394 CMYC 
+ 0.0887 P53 
Predictor Coef Stdev t-ratio p 
Constant == 0.6251 0.1472 4.25 0.000 
NM23 0.4063 0.1443 2.82 0.009 
PCNA 0.10168 0.03832 2.65 0.014 
MIBc -0.12002 0.04967 -2.42 0.023 
CMYC -0.3942 0.2168 -1.82 0.081 
P53 - 0.08873 0.06753 1.31 0.201 
s=0.4416 R-sq = 45.1% R-sq(adj) = 34.1% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 5 3.9985 0.7997 4.10 0.007 
Error . 25 4.8762 0.1950 Total 30 8.8747 
SOURCE DF SEQ SS 
NM23 1 1.8651 
PCNA 1 0.7297 
MIBc 1 0.5870 
CMYC 1 0.4801 
P53 1 0.3367 
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Unusual Observations -4 
Obs. NM23 log surv Fit Stdev. Fit Residual St. Resid 
20 0.00 1.0414 0.1722 0.2072 , 0.8692 2.23R 
R denotes an obs. with a large st. resid. 
Regression Analysis on PCNA 
The regression equation is 
log surv = 0.611 + 0.0885 PCNA 
Predictor Coef Stdev t-ratio p 
Constant 0.6109- 0.1498 4.08 0.000 
PCNA 0.08852 0.04032 2.20 0.036 
s=0.5123 R-sq = 14.2% R-sq(adj) = 11.3% 
Analysis of Variance 
SOURCE DF - SS MS Fp 
Regression 1 1.2645 1.2645 4.82 0.036 
Error 29 7.6101 0.2624 
Total'. 30 8.8747 
Regression Analysis on Mibc 
The regression equation is 
log surv = 0.899 - 0.0144 MIBc 
Predictor Coef Stdev t-ratio p 
Constant 0.8987 0.1310 6.86 0.000 
MIBc ;1- -0.01442 0.04361 -0.33 0.743 
s=0.5522 R-sq = 0.4% R-sq(adj) = 0.0% 
Analysis of Variance 
SOURCE r' DF SS MS Fp 
Regression 1 0.0333 0.0333 0.11 0.743 
Error 29 8.8413 0.3049 
Total 30 , 8.8747 
iry _ . ýS ,. 3 ., 
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Regression Analysis on chemo, radio and PCNA 
The regression equation is 
log sure =-0.056 + 0.583 chemo + 0.364 radio + 0.0933 PCNA 
Predictor Coef Stdev t-ratio p 
Constant -0.0563 0.2554 -0.22 0.827 
chemo 0.5827' 0.2237 2.60 0.015 
radio 0.3641 0.1646 2.21 0 . 036 PCNA 0.09329 0.03591 2.60 0.015 
s=0.4508 R-sq = 38.2% R-sq(adj) = 31.3% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 3 3.3877 1.1292 5.56 0.004 
Error 27 5.4870 0.2032 
Total 30 8.8747 
SOURCE DF SEQ SS 
chemo -10.8194 
radio 1 1.1967 
PCNA 1 1.3716 
Unusual Observations 
Obs. chemo log surv Fit Stdev. Fit Residual St. Resid 
2 1.00 0.0000 0.8852 0.1204 -0.8852 -2.04R 
R denotes an obs. with a large st. resid. 
Regression Analysis on chemo, radio, PCNA and Mibc 
The regression equation is 
log surv =-0.012 + 0.581 chemo + 0.400 radio + 0.117 PCNA - 0.0655 MIBc 
Predictor Coef Stdev t-ratio p 
Constant -0.0117 0.2474 -0.05 0.963 
chemo 0.5810 0.2155 2.70 0.012 
radio 0.4004 0.1599 2.50 0.019 
PCNA 0.11689 0.03711 3.15 0.004 
MIBc -0.06554 0.03730 -1.76 0.091 
s=0.4343 R-sq = 44.7% R-sq(adj) = 36.2% 
Analysis of Variance 
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SOURCE DF SS MS Fp 
Regression 4- 3.9701 0.9925 5.26 0.003 
Error 26 4.9045 0.1886 
Total 30 8.8747 
SOURCE DF SEQSS 
chemo 1 0.8194 
radio 1 1.1967 
PCNA 1 1.3716 
MIBc 1 0.5824 
Unusual Observations 
Obs. chemo log surv Fit Stdev. Fit Residual St. Resid 
21 1.00 1.2788 0.2932 0.1942 0.9855 2.54R 
R denotes an obs. with a large st. resid. 
Regression Analysis on chemo, radio, PCNA, Mibc and p53 
The regression equation is 
log surv =-0.151 + 0.699 chemo + 0.403 radio + 0.115 PCNA - 0.135 MIBc 
+ 0.154 P53 
Predictor Coef Stdev t-ratio p 
Constant -0.1509 - 0.2261 -0.67 0.511 
chemo 0.6988 0.1967 3.55 0.002 
radio 0.4028 0.1426 2.82 0.009 
PCNA 0.11537 0.03308 3.49 0.002 
MIBc -0.13479 0.04155 -3.24 0.003 
P53 0.15402 0.05541 2.78 0.010 
s=0.3871 R-sq = 57.8% R-sq(adj) = 49.3% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 5 5.1280 1.0256 6.84 0.000 
Error 25 3.7467 0.1499 
Total 30 8.8747 
SOURCE DF SEQ SS 
chemo 1 0.8194 
radio 1 1.1967 
PCNA 1 1.3716 
MIBc 1 0.5824 
P53 1 1.1578 
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Best Subsets Regression on biological data 
Response is log surv 
Adj. 
Vars R-sq R-sq C-p s 
1 21.0 18.3 8.3 0.49164 
1 14.2 11.3 11.3 0.51227 
1 6.4 3.2 14.8 0.53507 
1 3.5 0.2 16.1 0.54339 
1 0.7 0.0 17.4 0.55124 
2 29.2 24.2 6.6 0.47359 
2 26.3 21.0 7.9 0.48328 
2 23.8 18.4 9.0 0.49138 
2 23.4 18.0 9.2 0.49263 
2 23.0 17.5 9.4 0.49406 
3 35.9 28.7 5.7 0.45918 
3 33.1 25.7 6.9 0.46896 
3 32.3 24.8 7.2 0.47164 
3 32.1 24.5 7.4 0.47247 
3 31.9 24.3 7.4 0.47323 
4 41.3 32.2 5.3 0.44777 
4 38.3 28.8 6.6 0.45896 
4 38.2 28.7 6.6 0.45938 
4 38.1 28.6 6.7 0.45964 
4 37.8 28.2 6.8 0.46081 
5 45.1 34.1 5.6 0.44164 
5 44.9 33.9 5.6 0.44225 
5 43.2 31.8 6.4 0.44919 
5 42.5 31.0 6.7 0.45187 



















































Best Subsets Regression on biological and clinical data 
Response is log surv 
C 
E 
R c r 
P M N B h a s 
C I M B Pe d u 
Adj. N B 2 2 5m i r 
Vars R-sq R-sq C-p s A c 3 m 3o o g 
1 21.0 18.3 14.8 0.49164 X 
1 20.5 17.8 15.0 0.49325 X 
1 14.2 11.3 18.3 0.51227 X 
1 10.5 7.4 20.3 0.52329 X 
1 9.2 6.1 21.0 0.52704 X 
2 29.2 24.2 12.4 0.47359 X X 
2 28.9 23.8 12.6 0.47465 X X 
2 27.1 21.9 13.5 0.48063 X X 
2 27.0 21.8 13.6 0.48111 X X 
2 26.3 21.0 14.0 0.48328 X X 
3 38.2 31.3 9.7 0.45080 X X X 
3 35.9 28.7 10.9 0.45918 X X X 
3 35.5 28.4 11.1 0.46030 X X X 
3 34.6 27.3 11.6 0.46367 X X X 
3 34.5 27.3 11.6 0.46388 X X X 
4 44.7 36.2 8.2 0.43432 X X X X 
4 44.3 35.7 8.5 0.43601 X X XX 
4 42.7 33.9 9.3 0.44220 X X X X 
4 42.5 33.6 9.4 0.44318 X X X X 
4 40.9 31.8 10.2 0.44905 X X X X 
5 57.8 49.3 3.3 0.38713 X X XX X 
5 50.0 40.0 7.4 0.42113 X X X X X 
5 47.6 37.1 8.7 0.43137 X X X X X 
5 46.5 35.9 9.3 0.43562 X X X XX 
5 45.5 34.6 9.8 0.43969 X X X X X 
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